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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 22, Revision 1 
(FGE.22Rev1): 
Ring-substituted phenolic substances from chemical groups 21 and 251 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate 28 flavouring substances in the Flavouring Group 
Evaluation 22, Revision 1, using the Procedure in Commission Regulation (EC) No 1565/2000. The 
substance 3,4-methylenedioxyphenol [FL-no: 04.080] was reported to have a genotoxic potential in 
vitro, while in vivo studies were not available. Therefore, the Panel concluded that the Procedure could 
not be applied to this substance until adequate genotoxicity data become available. The remaining 27 
substances were evaluated through a stepwise approach (the Procedure) that integrates information on 
structure-activity relationships, intake from current uses, toxicological threshold of concern, and 
available data on metabolism and toxicity. The Panel concluded that these 27 candidate substances do 
not give rise to safety concerns at their levels of dietary intake, estimated on the basis of the MSDI 
approach. Adequate specifications for the materials of commerce are available for all 27 flavouring 
substances evaluated through the Procedure. 
 
© European Food Safety Authority, 2011 
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SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate 28 flavouring substances in the 
Flavouring Group Evaluation 22, Revision 1 (FGE.22Rev1) using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000. The flavouring substance belongs to chemical group 30, 
Annex I of the Commission Regulation (EC) No 1565/2000. 
The 28 candidate substances are ring substituted phenolic substances belonging to chemical groups 21 
and 25. 
Two of the candidate substances have a chiral centre, the commercial product of both substances are 
the racemate. 
Twenty-five of the flavouring substances are classified into structural class I and three are classified 
into structural class II [FL-no: 04.091, 04.092 and 07.234]. 
Twenty-two of the flavouring substances in the present group have been reported to occur naturally in 
a wide range of food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
 
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
 
According to the default MSDI approach, the 28 flavouring substances in this group have intakes in 
Europe from 0.001 to 610 microgram/capita/day, which are all below the thresholds of concern for 
their respective class of 1800 microgram/person/day for structural class I or 540 
microgram/person/day for structural class II substances. 
 
One of the flavourings substances, 3,4-methylenedioxyphenol [FL-no: 04.080], was reported to have a 
genotoxic potential in vitro, while in vivo studies were not available for this candidate substance. 
Therefore, the Panel decided that the Procedure could not be applied to this candidate substance until 
adequate genotoxicity data become available. The genotoxicity data available did not preclude an 
evaluation of the other 27 candidate flavouring substances in this Flavouring Group Evaluation 
through the Procedure. 
The candidate substances in this group are conjugated with glucuronic acid or sulphate very efficiently 
and these pathways are not easily saturated. At high dose levels reactive metabolites (quinones, 
catechols, quinone methides) may be formed, but it is not expected that, at the levels of intake from 
the use as flavouring substances, the formation of these metabolites would overwhelm detoxication 
capacity through conjugation with sulphate, glucuronic acid or in particular glutathione. Thus, it is 
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concluded that all 27 candidate substances in this group, which have been evaluated using the 
Procedure, may be expected to be metabolised to innocuous products at the estimated levels of intake, 
based on the MSDI approach. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It was considered that on the basis of the default MSDI approach the 27 candidate substances 
evaluated through the Procedure would not give rise to safety concerns at the estimated levels of 
intake arising from their use as flavouring substances. The total combined intake of the candidate and 
supporting substances belonging to structural class I is approximately 3900 microgram/capita/day, 
which exceeds the threshold of concern for a compound belonging to structural class I of 1800 
microgram/person/day. The main contribution to the MSDI of 3900 microgram/capita/day originates 
from one supporting substance, 4-(p-hydroxyphenyl)butan-2-one [FL-no: 07.055], for which the 
estimated daily per capita intake is 2400 microgram. For this supporting substance a 13 week study 
provides a NOAEL of 100 mg/kg bw/day, which gives a margin of safety of 2500 to the MSDI value. 
The estimated intakes for the 24 candidate substances evaluated through the Procedure and belonging 
to structural class I, range from 74 to 35000 microgram/person/day based on the mTAMDI. The 
mTAMDI is above the threshold of concern of 1800 microgram/person/day for two of the candidate 
substances [FL-no: 08.134 and 09.946].  
The estimated intakes of the three substances evaluated through the Procedure and belonging to 
structural class II, are 420 microgram/person/day based on the mTAMDI, which is below the threshold 
of concern for structural class II substances of 540 microgram/person/day. 
Thus, for two candidate substances [FL-no: 08.134 and 09.946], for which the mTAMDI is above the 
threshold, further information is required. This would include more reliable intake data and then, if 
required, additional toxicological data. 
The 25 substances which have mTAMDI intake estimates below the threshold of concern for their 
structural class are also expected to be metabolised to innocuous products. 
In order to determine whether the conclusion for the 27 candidate substances evaluated using the 
Procedure can be applied to the materials of commerce, it is necessary to consider the available 
specifications. Adequate specifications including complete purity criteria and identity tests for the 
materials of commerce have been provided for all 27 flavouring substances evaluated through the 
Procedure. 
Thus, the Panel concluded that for one candidate substance [FL-no: 04.080] additional genotoxicity 
data are required and that the remaining 27 candidate substances would present “no safety concern at 
the estimated level of intakes, based on the MSDI approach. 
KEYWORDS  
Phenolic, ring-alkyl, ring-alkoxy, flavourings, food safety, FGE.22. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2008/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The FGE is revised to include substances for which data were submitted after the deadline as laid 
down in Commission Regulation (EC) No 622/2002 and to take into account additional information 
that has been made available since the previous Opinion on this FGE.  
The Revision also includes newly notified substances belonging to the same chemical groups 
evaluated in this FGE. 
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
HISTORY OF THE EVALUATION  
 
FGE Opinion adopted 
by EFSA 
Link No. of candidate 
substances 
FGE.22 27 September 2006 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1178620772628.htm 
23 
FGE.22Rev1 4 February 2011  28 
 
The present revision of FGE.22, FGE.22Rev1, includes the assessment of five newly notified 
candidate substances [FL-no: 08.134, 09.943, 09.944, 09.945 and 09.946]. For one of these substances 
[FL-no: 08.134] supporting metabolism data have been submitted. No other data have been provided. 
A search in open literature did not provide any new pertinent data on toxicity or metabolism. 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register prior to their authorisation and inclusion in a Union List according to 
Commission Regulation (EC) No 1565/2000 (EC, 2000a).  
In addition, in letter of 11 May 2009  the Commission requested EFSA to carry out a risk assessment 
on guaiacol propionate [FL-no: 09.943], guaiacol butyrate [FL-no: 09.944], guaiacol isobutyrate [FL-
no: 09.945], dihydrogalangal acetate  [FL-no: 09.946] and nibovan [FL-no: 08.134] in accordance 
with Commission Regulation (EC) No 1565/2000 (EC, 2000a): 
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“The European Commission requests the European Food Safety Authority to carry out a risk 
assessment on eighteen new flavouring substances in accordance with Commission Regulation (EC) 
No 1565/2000, if possible by the end of the evaluation programme, if not within nine months from the 
finalisation of that programme”. 
The deadline of the “Terms of Reference” was negotiated to 31 May 2011.  
The remaining 13 substances of the “Terms of Reference” of 11 May 2009 were evaluated in other 
FGEs. 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 22, Revision 1 
1.1. Description 
The present Flavouring Group Evaluation 22, Revision 1, FGE.22Rev1, using the Procedure as 
referred to in the Commission Regulation EC No 1565/2000 (EC, 2000a) (the Procedure – shown in 
schematic form in Annex I), deals with 28 ring-substituted phenolic substances. The group comprises: 
• nine mono-, di- or tri-alkyl substituted phenols,  
• three esters of alkyl-substituted phenols,  
• three alkoxy-substituted phenols,  
• three esters of alkoxy-substituted phenols,  
• three alkoxy-substitued phenols with an alkenyl substituent or an alkyl substituent containing 
a keto-function or an hydroxycarboxylic acid,  
• 4-hydroxyacetophenone,  
• two alkoxy-substituted 4-hydroxyacetophenones,  
• an alkoxy-substituted 4-hydroxypropiophenone,  
•  two 4-hydroxybenzylethers, 
• an ester of 4-hydroxy-1-phenyl-1-propanol.  
These flavouring substances belong to chemical groups 21 and 25, Annex I of Commission Regulation 
(EC) No 1565/2000 (EC, 2000a). 
The 28 flavouring substances (candidate substances) under consideration, as well as their chemical 
Register names, FLAVIS- ( FL-), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-), and 
Flavor and Extract Manufactures Association- (FEMA-) numbers, structure and specifications, are 
listed in Table 1. 
The outcome of the safety evaluation is summarised in Table 2a. 
The 28 candidate substances are structurally closely related to 40 flavouring substances (supporting 
substances in the group of “Phenol and phenol derivatives” evaluated at the 55th JECFA meeting 
(JECFA, 2001a). These substances, with the respective structural formulas, FEMA, CoE, and CAS 
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register numbers, evaluation status by Scientific committee on Food (SCF), JECFA, and by CoE and 
the European Maximised Survey-derived Daily Intake (MSDI) values, are listed in Table 3.  
The hydrolysis products of the candidate esters are listed in Table 2b. 
In the original JECFA evaluation, from which the supporting substances for this FGE have been taken, 
phenol [FL no: 04.041] was also included. However, the Panel concluded (EFSA, 2006a) that phenol 
should not be used as supporting substance to evaluate the toxicity of the ring-substituted phenols in 
this FGE, because – in contrast to phenol – the formation of toxic metabolites like hydroquinones and 
quinones is not expected to be of significance for the candidate ring-substituted phenols at their 
estimated levels of intake as flavouring substances. 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
Two of the candidate substances possess a chiral centre [FL-no: 08.134 and 09.946]. For both 
substances industry has informed that the commercial compound is the racemate (Flavour Industry, 
2009k). 
1.3. Natural Occurrence in Food 
Twenty-two of the 28 candidate substances have been reported to occur in one or more of the 
following food items: coffee, fish, alcoholic beverages, spices, milk powder, fruits, asparagus, pork 
and wort. Quantitative data on the natural occurrence in food have been reported for 16 of the 
candidate substances. These reports include: 
• 3,5-Dimethylphenol [FL-no: 04.020]: 0.1 mg/kg in tamarind. 
• 3-Ethylphenol [FL-no: 04.021]: up to 1.4 mg/kg in coffee. 
• 2,6-Dimethoxy-4-vinylphenol [FL-no: 04.061]: up to 0.03 mg/kg in beer, 1.8 mg/kg in coffee, 
and 0.05 mg/kg in wort. 
• 2,3-Dimethylphenol [FL-no: 04.065]: 2.1 mg/kg in beer. 
• 2,4-Dimethylphenol [FL-no: 04.066]: 2 mg/kg in coffee. 
• 2-Ethylphenol [FL-no: 04.070]: 1.7 mg/kg in coffee, up to 0.4 mg/kg in lean fish, 0.05 mg/kg 
in sherry, 0.002 mg/kg in whisky, 0.001 mg/kg in red wine. 
• 4-Isopropylphenol [FL-no: 04.073]: up to 1900 mg/kg in cumin seed. 
• 4-Methoxyphenol [FL-no: 04.077]: less than 500 mg/kg in galangal. 
• 5-Methyl-2-(tert-butyl)phenol [FL-no: 04.078]: 0.0051 mg/kg in milk powder. 
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• 4-Hydroxybenzyl methyl ether [FL-no: 04.092]: 200 mg/kg in bourbon vanilla. 
• Acetovanillone [FL-no: 07.142]: 0.08 mg/kg in asparagus, 0.15 mg/kg in cloudberry, up to 4 
mg/kg in coffee, up to 0.6 mg/kg in lean fish, 9.3 mg/kg in pork, up to 0.03 mg/kg in beer, 
0.15 mg/kg in sherry, up to 1227 mg/kg in red wine, up to 0.09 mg/kg in wort. 
• 4-Hydroxy-3,5-dimethoxyacetophenone [FL-no: 07.164]: 4.4 mg/kg in pork, 0.025 mg/kg in 
sherry. 
• 4-Hydroxyacetophenone [FL-no: 07.243]: 2.1 mg/kg in cloudberry, up to 3.2 mg/kg in coffee, 
trace amounts in cranberry, up to 0.04 mg/kg in mango, 0.4 mg/kg in sherry, 0.01 mg/kg in 
wort. 
• 2-Isopropyl-5-methylphenyl acetate [FL-no: 09.253]: less than 1000 mg/kg in thyme. 
• Carvacryl acetate [FL-no: 09.337]: up to 1100 mg/kg in thyme. 
• Dihydrogalangal acetate [FL-no: 09.946]: 5 mg/kg in galangal roots (Yang et al., 2009) 
The remaining six substances (3,4-methylenedioxyphenol [FL-no: 04.080], 2-isopropyl-5-
methylphenyl formate [FL-no: 09.893], nibovan [FL-no: 08.134], guaiacol propionate [FL-no: 
09.943], guaiacol butyrate [FL-no: 09.944] and guaiacol isobutyrate [FL-no: 09.945] have not been 
reported to occur naturally in any food items according to TNO (TNO, 2000; TNO, 2010) 
2. Specifications 
Purity criteria for the 28 substances have been provided by the Flavour Industry (EFFA, 2004c) (Table 
1). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000a), this information is adequate for all 28 candidate substances (see Section 1.2 and Table 1). 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
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beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
In the present FGE.22Rev1 the total annual production volume of the 28 candidate substances for use 
as flavouring substances in Europe was reported to be 7120 kg (EFFA, 2004h; Flavour Industry, 
2009k). For the 40 supporting substances the total annual volume of production in Europe is 
approximately 25000 kg, (4-(p-hydroxyphenyl)butan-2-one [FL-no: 07.055] accounts for 
approximately 19000 kg) (JECFA, 2001b). 
On the basis of the annual volumes of production reported for the 28 candidate substances, the MSDI 
values for each of these flavourings have been estimated (Table 2a). Approximately 99 % of the total 
annual volume of production for the candidate substances is accounted for by the five new substances 
included in FGE.22Rev1 [FL-no: 08.134, 09.943, 09.944, 09.945 and 09.946]. The estimated daily per 
capita intakes of these five candidate substances from use as flavouring substances are 120, 43, 43, 43 
and 610 microgram, respectively. The daily per capita intakes for each of the remaining substances is 
2.2  microgram or less (Table 2a). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are available, and is 
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available for 
the enlarged EU. 
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For the present evaluation of the 28 candidate substances, information on food categories and normal 
and maximum use levels5,6,7 has been submitted by the Flavour Industry (EFFA, 2004g; EFFA, 2007a; 
Flavour Industry, 2009k). The 28 candidate substances are used in flavoured food products divided 
into the food categories, outlined in Annex III of the Commission Regulation 1565/2000 (EC, 2000a), 
as shown in Table 3.1. For the calculation of the mTAMDI, the reported normal use levels were used. 
In the case where different use levels were reported for different food categories the highest reported 
normal use level was used. 
 
Table 3.1 Use of Candidate Substances 
Food 
categor
y 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 All but [FL-no: 09.943, 09.944, 09.945, 09.946] 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All but [FL-no: 08.134, 09.943, 09.944, 09.945, 
09.946] 
03.0 Edible ices, including sherbet and sorbet All but [FL-no: 09.946] 
04.1 Processed fruits All but [FL-no: 08.134, 09.943, 09.944, 09.945, 
09.946] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & 
tubers, pulses and legumes), and nuts & seeds 
None 
05.0 Confectionery All 28 
06.0 Cereals and cereal products, incl. flours & starches from 
roots & tubers, pulses & legumes, excluding bakery 
All but [FL-no: 09.946] 
07.0 Bakery wares All but [FL-no: 09.946] 
08.0 Meat and meat products, including poultry and game All but [FL-no: 08.134, 09.943, 09.944, 09.945] 
09.0 Fish and fish products, including molluscs, crustaceans 
and echinoderms  
All but [FL-no: 08.134, 09.943, 09.944, 09.945] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey [FL-no: 09.943, 09.944, 09.945, 09.946] 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All but [FL-no: 09.943, 09.944, 09.945] 
13.0 Foodstuffs intended for particular nutritional uses All but [FL-no: 08.134, 09.943, 09.944, 09.945, 
09.946] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All 28 
14.2 Alcoholic beverages, incl. alcohol-free and low-
alcoholic counterparts 
All 28 
15.0 Ready-to-eat savouries All but [FL-no: 08.134] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) 
- foods that could not be placed in categories 1 – 15 
All but [FL-no: 09.946] 
 
According to the Flavour Industry the normal use levels for the 28 candidate substances are in the 
range of 0.1 to 500 mg/kg food, and the maximum use levels are in the range of 1 to 1000 mg/kg 
(EFFA, 2004g; EFFA, 2007a; Flavour Industry, 2009k). 
The mTAMDI values for the 25 candidate substances from structural class I (see Section 5) range 
from 74 to 35000 microgram/person/day. For each of the remaining three candidate substances from 
structural class II (see section 5) the mTAMDI values are 420 microgram/person/day. 
                                                     
 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004e). 
7 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 
“Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 2007a). 
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For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II 
4. Absorption, Distribution, Metabolism and Elimination 
The phenolic substances in this group are assumed to be well absorbed. The substances are readily 
conjugated with sulphate or glucuronic acid at the hydroxy group, followed by rapid excretion usually 
via urine. The seven  phenol esters will be hydrolysed, probably in the intestinal lumen by pancreatic 
enzymes to the corresponding phenols and carboxylic acids (see Table 2b).  The carboxylic acids will 
be rapidly metabolised and have been considered innocuous in previous evaluations ([FL no: 08.001, 
08.002, 08.003 and 08.005] in FGE.02Rev1 (EFSA, 2008ag) and [FL no: 08.006] in FGE.01Rev2 
(EFSA, 2010t) 
Sulphation and glucuronidation of phenols have been found in many species including humans, but 
species differences in efficacy of the two routes have been reported especially with phenol itself. The 
available data indicate that the efficacy of the conjugation reactions is not substantially influenced by 
the presence of ring substituents, provided that these are not too bulky. 
Ring hydroxylation, side chain oxidation and O-demethylation occur to a much smaller extent than 
conjugation, owing to the efficiency of the conjugation reactions. Products of the oxidative metabolic 
pathways may include quinones and catechols which may trigger a cytotoxic response if their 
formation rate overwhelms their detoxication via glutathione conjugation. Reduced quinones (i.e. 
hydroquinones) and catechols are also substrates for sulphate and glucuronic acid conjugation.  
In vitro metabolism studies have provided evidence of a bio-activation pathway for para-substituted 
alkylphenols. This pathway involves formation of quinone methides, which can be effectively 
detoxified by enzymatic or spontaneous conjugation with glutathione. As long as the intra-cellular 
concentration of glutathione is maintained, these quinone methides may not reach concentrations high 
enough to trigger a toxic response. Also the presence of other ring substituents affects the reactivity of 
the quinone methide intermediates, e.g. for 2,6-dimethoxy-4-vinylphenol [FL-no: 04.061] the two 
methoxy groups may mitigate cytotoxic properties. 
The candidate substances with a ketonic side chain possess an additional option for metabolism. Such 
phenol derivatives may also be excreted in the urine as glucuronic acid or sulphate conjugates but 
reduction of the ketone to the secondary alcohol has also been reported. Minor metabolites may be 
formed through ring hydroxylation and side chain omega-oxidation may result in chain length 
reduction. 
The candidate substance nibovan [FL-no: 08.134] is an endogenous metabolite of adrenalin and nor-
adrenalin. This substance is rapidly eliminated from the blood and excreted via the kidneys. Data on 
conjugations are not available, but due to  the chemical structure, conjugation may be anticipated 
similar to what has been described above for phenol. In addition, direct conjugation of the carboxylic 
acid moiety with amino acids has been described for phenylacetic acid (EFSA, 2009f) and this may 
also occur with nibovan. It has been described that decarboxylation of the carboxylic acid moiety is 
also an option, leading to the formation of benzoic acid which can be converted to the corresponding 
glycine conjugate. 
The candidate substances in this group are conjugated with glucuronic acid or sulphate very 
efficiently, and these pathways are not easily saturated at the expected levels of intake resulting from 
their use as flavouring substances. At high dose levels reactive metabolites (quinones, catechols, 
quinone methides) may be formed. However, the formation of these metabolites is not expected to 
overwhelm the detoxication capacity through conjugation with sulphate, glucuronic acid or in 
particular glutathione, when the substances are used as flavouring substances.  
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Thus, it is concluded that in general, the substances in this group may be expected to be metabolised to 
innocuous substances at the estimated levels of intake, based on the MSDI approach. 
For more detailed information, see Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
One of the candidate substances, 3,4-methylenedioxyphenol [FL-no: 04.080] showed genotoxic 
potential in vitro. Therefore, the Panel decided that the Procedure could not be applied to this 
candidate substance until adequate genotoxicity data become available. 
For the safety evaluation of the remaining 27 candidate substances from chemical groups 21 and 25 
the Procedure as outlined in Annex I was applied, based on the MSDI approach. The stepwise 
evaluations of the 27 substances are summarised in Table 2a. 
Step 1 
Twenty-four of the 27 candidate substances to which the Procedure could be applied are classified into 
structural class I, and three candidate substances are classified into structural class II. 
Step 2 
Based on the available data the 24 candidate substances from structural class I and three candidate 
substances from structural class II may be expected to be metabolised to innocuous substances at the 
estimated levels of intake. Therefore, these 27 flavouring substances proceed along the A-side of the 
Procedure. 
Step A3 
According to the default MSDI approach, the 27 flavouring substances in this group have intakes in 
Europe from 0.001 to 610 microgram/capita/day, which are all below the thresholds of concern for 
their respective class of 1800 microgram/person/day for structural class I or 540 
microgram/person/day for structural class II substances. 
Accordingly, these 27 candidate substances are not expected to be of safety concern at their estimated 
levels of intake, based on the MSDI approach. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The estimated intakes for the 24 candidate substances evaluated through the Procedure and belonging 
to structural class I, range from 74 to 35000 microgram/person/day based on the mTAMDI. The 
mTAMDI is above the threshold of concern of 1800 microgram/person/day for two of the candidate 
substances [FL-no: 08.134 and 09.946].  
The estimated intakes of the three substances evaluated through the Procedure and belonging to 
structural class II, are 420 microgram/person/day based on the mTAMDI, which is below the threshold 
of concern for structural class II substances of 540 microgram/person/day. 
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For comparison of the MSDI and mTAMDI values, see Table 6.1 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
04.020 3,5-Dimethylphenol 0.037 420 Class I 1800 
04.021 3-Ethylphenol 0.073 420 Class I 1800 
04.061 2,6-Dimethoxy-4-vinylphenol 1.2 420 Class I 1800 
04.065 2,3-Dimethylphenol 0.013 420 Class I 1800 
04.066 2,4-Dimethylphenol 0.011 420 Class I 1800 
04.070 2-Ethylphenol 0.037 420 Class I 1800 
04.072 3-Isopropylphenol 0.0012 420 Class I 1800 
04.073 4-Isopropylphenol 0.24 420 Class I 1800 
04.076 3-Methoxyphenol 0.011 420 Class I 1800 
04.077 4-Methoxyphenol 0.12 420 Class I 1800 
04.078 5-Methyl-2-(tert-butyl)phenol 0.061 420 Class I 1800 
04.095 2,4,6-Trimethylphenol 0.0097 420 Class I 1800 
07.142 Acetovanillone 2.2 420 Class I 1800 
07.154 1-(3,5-Dimethoxy-4-hydroxyphenyl)propan-
1-one 
0.026 420 Class I 1800 
07.164 4-Hydroxy-3,5-dimethoxyacetophenone 0.24 1600 Class I 1800 
07.243 4-Hydroxyacetophenone 0.016 1600 Class I 1800 
08.134 Nibovan 120 5000 Class I 1800 
09.253 2-Isopropyl-5-methylphenyl acetate 1.1 420 Class I 1800 
09.337 Carvacryl acetate 0.61 420 Class I 1800 
09.893 2-Isopropyl-5-methylphenyl formate 0.52 420 Class I 1800 
09.943 Guaiacol propionate 43 74 Class I 1800 
09.944 Guaiacol butyrate 43 74 Class I 1800 
09.945 Guaiacol isobutyrate 43 74 Class I 1800 
09.946 Dihydrogalangal acetate 610 35000 Class I 1800 
04.080 3,4-Methylenedioxyphenol 1.7 420 Class I 1800 
04.091 Ethyl 4-hydroxybenzyl ether 0.0012 420 Class II 540 
04.092 4-Hydroxybenzyl methyl ether 0.61 420 Class II 540 
07.234 5-Paradol 0.012 420 Class II 540 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
One of the candidate substances, 3,4-methylenedioxyphenol [FL-no: 04.080] showed genotoxic 
potential in vitro and therefore the Procedure could not be applied to this substance. Accordingly, the 
substance will not be considered in the combined intake. 
On the basis of the reported annual production volumes in Europe (EFFA, 2004h; Flavour Industry, 
2009k), the combined estimated daily per capita intake as flavourings of the 24 candidate flavouring 
substances assigned to structural class I and of the three candidate substances belonging to structural 
class II are 867 and 0.6 microgram, respectively. These values do not exceed the thresholds of concern 
for substances belonging to structural class I of 1800 microgram/person/day and to structural class II 
of 540 microgram/person/day. 
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The 27 candidate substances are structurally related to 40 supporting substances evaluated by JEFCA 
at its 55th meeting (JECFA, 2001b). Based on reported production volumes, European per capita 
intakes (MSDI) could be estimated for all 40 supporting substances.  
The 40 supporting substances belong to structural class I. The total combined intake of the candidate 
and supporting substances belonging to structural class I is approximately 3900 microgram/capita/day, 
which exceeds the threshold of concern for a compound belonging to structural class I of 1800 
microgram/person/day. The main contribution to the MSDI of 3900 microgram/capita/day originates 
from one supporting substance, 4-(p-hydroxyphenyl)butan-2-one [FL-no: 07.055], for which the 
estimated daily per capita intake is 2400 microgram. For this supporting substance a 13 week study 
provides a NOAEL of 100 mg/kg body weight (bw)/day, which gives a margin of safety of 2500 to the 
MSDI value (Gaunt et al., 1970). 
Therefore, it can be concluded that the total combined intakes of the 27 candidate substances and the 
40 supporting substances do not pose a safety concern. 
8. Toxicity 
8.1. Acute Toxicity 
Data are available for six of the 28 candidate substances [FL-no: 04.021, 04.065, 04.020, 04.078, 
04.077 and 07.243] and for 21 supporting substances. Oral LD50 values are in the range of 120 to more 
than 5000 mg/kg bw in rat, mice and rabbit. 
The acute toxicity data are summarised in Annex IV, Table IV.1 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Data are available for three of the 23 candidate substances [FL-no: 04.066, 04.077 and 04.080] and for 
10 supporting substances. 
Groups of male (N=10) and female (N=10) rats were dosed with 0, 60, 180 or 540 mg/kg bw/day of 
2,4-dimethylphenol [FL-no: 04.066] by gavage for 90 days. No significant differences related to the 
treatment with 2,4-dimethylphenol were observed on clinical chemistry and haematological 
parameters. Histopathological examination of the stomach was performed on all surviving animals. 
Further, other tissues from the control group and the groups dosed with 180 and 540 mg/kg bw/day, 
respectively, were also examined histologically. Significant findings were hyperkeratosis and 
epithelial hyperplasia of the forestomach in 100 % of the males (540 and 180 mg/kg bw/day), 100 % 
of the females (540 mg/kg bw/day) and 60 % of the females (180 mg/kg bw/day). The effect was 
ascribed to the irritant properties of 2,4-dimethylphenol. The No Observed Adverse Effect Level 
(NOAEL) derived was 60 mg/kg bw/day (Daniel et al., 1993). 
Three short term oral dosing studies in rats and rabbits ranging from 4 to 9 weeks are available on 4-
methoxyphenol [FL-no: 04.077]. In two of these studies the only effects observed were changed body 
and organ weights (Hodge et al., 1949). In another study 4-methoxyphenol was reported to strongly 
affect the forestomach mucosa with hyperplasia and mild keratosis in rats fed 2 % of the substance in 
the feed for 4 to 8 weeks (Altmann et al., 1985; Altmann et al., 1986).  
Groups of 15 male hamsters were administered diets containing 0 or 1.5 % 4-methoxyphenol for 20 
weeks. Induction of hyperplasia in the forestomach was observed in all dosed animals (Hirose et al., 
1986). 
Groups of 10-11 male rats were administered diets containing 0 or 2 % 4-methoxyphenol for 24-48 
weeks. One group in addition received basal diet for 24 weeks after dosing. Hyperplasia in the 
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forestomach was induced in all treated animals. Simple or papillary hyperplasia but not basal cell 
hyperplasia was clearly regressed in the recovery group receiving basal diet after cessation of dosing 
(Kagawa et al., 1993). 
Male and female rats (N=30/sex) were given diets with 0 or 2 % 4-methoxyphenol for 104 weeks. 
Histopathological examination of the forestomach showed atypical hyperplasia (male, 67 %, female, 
37 %), papillomas (50 %, 23 %) and squamos cell carcinomas (77 %, 20 %) (Asakawa et al., 1994). 
In a study on induction of forestomach tumours groups of male rats (N= 26-28) were given diets 
containing 0 or 0.4 % 4-methoxyphenol for 104 weeks. Treated animals had lower body weights than 
controls and an increased incidence of forestomach hyperplasia was observed. No carcinomas were 
detected (Hirose et al., 1997).  
Groups of 10-11 male rats were administered diets containing 0, 0.25, 0.5, 1 and 2 % of 4-
methoxyphenol for 51 weeks. Mild to severe hyperplasia was induced in the forestomach of rats given 
0.5 – 2 % of the test substance. Histopathological examination was only performed on liver, stomach, 
oesophagus and kidney. A NOAEL of 0.25 % corresponding to 125 mg/kg bw/day was derived (Wada 
et al., 1990). 
In an initiation-promotion study groups of male rats were given diets containing 0, 0.08 or 0.4 % of 4-
methoxyphenol for 24 weeks after initiation for 4 weeks with a combination of diethylnitrosamine, N-
methylnitrosourea, 1,2-dimethylhydrazine, N-butyl-N-(4-hydroxybutyl)-nitrosamine and 2,2’-
dihydroxy-di-n-propylnitrosamine. An increase in forestomach papillomas was observed in the high-
dose group but not in the low-dose group. Histopathological examination of other major organs 
showed no significant findings (Hirose et al., 1997). A NOAEL of 0.08 % in the diet corresponding to 
40 mg/kg bw/day was derived. 
Groups of 30 male and 30 female mice were fed a diet containing 0 or 2 % 3,4-methylenedioxyphenol 
[FL-no: 04.080] for 96 weeks. Squamous cell carcinomas were induced in the forestomach of  11 (38 
%) male and  5 (17 %) female mice (Tamano et al., 1992). 
Groups of 30 male and 30 female rats were fed a diet containing 0 or 2 % 3,4-methylenedioxyphenol 
for 104 weeks. Squamous cell carcinomas were induced in the forestomach of  9 (31 %) male and  3 
(10 %) female rats. Papillomas were observed in 10 (34 %) male and in 14 (47 %) female rats, but not 
in the mice. Hyperplasia was detected in almost all of the animals (Tamano et al., 1992). 
Groups of 10-11 male rats were dosed with 0 or 2 % 3,4-methylenedioxyphenol in the diet for 24-48 
weeks. In addition, one group received basal diet for 24 weeks after dosing. Hyperplasia in the 
forestomach was induced in all animals. Simple or papillary hyperplasia but not basal cell hyperplasia 
clearly regressed in the recovery group receiving basal diet after dosing (Kagawa et al., 1993). 
In a study on induction of forestomach tumours groups of male rats (N= 15-25) were dosed with 0 or 
0.4 % 3,4-methylenedioxyphenol in the diet for 104 weeks. Dosed animals had a lower body weight 
and increased relative liver and kidney weight compared to controls. There were no significant 
histopathological findings in the forestomach. No carcinomas were detected. (Hirose et al., 1997). 
In an initiation-promotion study groups of male rats were dosed with 0, 0.08 or 0.4 % of 3,4-
methylenedioxyphenol for 24 weeks after initiation for 4 weeks with a combination of 
diethylnitrosamine, N-methylnitrosourea, 1,2-dimethylhydrazine, N-butyl-N-(4-hydroxybutyl)-
nitrosamine and 2,2’-dihydroxy-di-n-propylnitrosamine. Histopathological examination of major 
organs showed no significant findings. The NOAEL derived was 0.4 % in the diet corresponding to 
200 mg/kg bw/day (Hirose et al., 1997). 
Forestomach hyperplasia were reported in studies on the candidate substances 2,4-dimethylphenol 
[FL-no: 04.066], 4-methoxyphenol [FL-no: 04.077] and 3,4-methylenedioxyphenol [FL-no: 04.080] 
and the supporting substances 4-methylphenol [FL-no: 04.028] and 4-(1,1-dimethylethyl)phenol [FL-
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no: 04.064]. 4-Methoxyphenol and 3,4-methylenedioxyphenol were also studied for tumour induction 
in long-term studies. The induction of tumours of the forestomach  is generally considered to result 
from irritant effects. Both duration of exposure and the dose are important determinants in the 
subsequent formation of forestomach tumours. These were observed in long term rodent studies (96-
104 weeks) with 4-methoxyphenol and 3,4-methylenedioxyphenol at 2 % but not at 0.4 % in diet. 
They are considered unlikely to occur at the estimated intakes when used as flavouring substances. In 
the light of the genotoxicity data discussed later for 3,4-methylenedioxyphenol, it is not possible to 
disregard the forestomach tumours, although it is recognised that they may also be formed via a non-
genotoxic mechanism. 
A 13-week oral feeding study in male and female rats given doses of 0.1, 0.2, 0.4 and 1 % in the diet is 
available for the supporting substance 4-(p-hydroxyphenyl)butan-2-one [FL-no: 07.055]. A slight 
increase in relative liver, adrenal and kidney weights was detected in male rats given 0.4 and 1 %. The 
NOAEL derived was 0.2 % in the diet corresponding to 100 mg/kg bw/day (Gaunt et al., 1970). 
The repeated dose toxicity data are summarised in Annex IV, Table IV.2 
8.3. Developmental / Reproductive Toxicity Studies 
Data on developmental and reproductive toxicity are available for three candidate substances [FL-no: 
04.076, 04.077 and 07.243] and for five supporting substances. No data are available on 
teratogenicity. 
Groups of 12-16 female rats were dosed orally with 0, 333, 667 or 1000 mg/kg bw of either 3-
methoxyphenol [FL-no: 04.076] or 4-methoxyphenol [FL-no: 04.077] or 4-hydroxyacetophenone [FL-
no: 07.243], once on day 11 of gestation. Maternal weight was measured at 24 and 72 hours, 
respectively, and litter size and pup weight were determined after delivery. 
Maternal weight change significantly different from the control was observed for 3-methoxyphenol 
and 4-methoxyphenol at all doses. 4-Hydroxyacetophenone did not result in maternal weight change 
different from the control at any dose. The only fetal effect detected was reduced litter size and fetal 
weight for 4-hydroxyacetophenone at the highest dose (Kavlock, 1990). 
The developmental / reproductive toxicity data are summarised in Annex IV, Table IV.3 
8.4. Genotoxicity Studies 
Data from in vitro tests are available for 12 candidate [FL-no: 04.020, 04.021, 04.065, 04.066, 04.070, 
04.076, 04.077, 04.080, 04.095, 07.142, 07.164 and 07.243] and 18 supporting substances. Data from 
in vivo tests are available for one candidate [FL-no: 04.077] and four supporting substances. Most 
studies are of limited or insufficient quality or are inadequately reported, thus for some of the studies 
the validity of the results could not be evaluated.  
Positive results were observed with three candidate substances [FL-no: 04.077, 04.080 and 07.142]. 
4-Methoxyphenol [FL-no: 04.077] did not induce gene mutations in bacteria (Haworth et al., 1983). In 
a gene mutation assay in mammalian cells (MLTK assay) a positive result was observed for 4-
methoxyphenol without metabolic activation and a negative result with metabolic activation using an 
S9 homogenate (Rogers-Back, 1986). In the test without metabolic activation an increase in the 
percentage of small colonies was noted indicating a potential for chromosomal aberrations. 4-
Methoxyphenol induced chromosomal aberrations in CHO cells in the presence and absence of 
metabolic activation (Putman, 1986). 4-Methoxyphenol did not induce sister chromatid exchanges in 
human lymphocytes (Jansson et al., 1988), however, the study was of limited quality. Since 4-
methoxyphenol did not induce chromosomal aberration in vivo in rat bone marrow cells after oral 
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application (Esber, 1986) the results observed in vitro with 4-methoxyphenol were considered to be of 
no concern. 
3,4-Methylenedioxyphenol [FL-no: 04.080] was reported to be negative in a bacterial mutagenicity 
assay in the presence and absence of metabolic activation while a positive result was reported in a 
gene mutation assay in mammalian cells (MLTK assay) both in the presence and absence of metabolic 
activation (Longfellow, 1985/1986). However, this information was only available as a very short 
abstract and the study reports were not available for evaluation. In vivo studies were not available for 
this candidate substance. 
Acetovanillone [FL-no: 07.142] was positive in a yeast assay without metabolic activation (Nestmann 
& Lee, 1983). This result is not considered to preclude the substance to be evaluated through the 
Procedure. The substance was negative in bacterial mutagenicity assays in the presence and absence of 
metabolic activation (Nestmann et al., 1980; Xu et al., 1984). However, reporting of the bacterial 
assays and the quality of data were insufficient and the validity of the results could not be evaluated.  
With the candidate substances 2-ethylphenol [FL-no: 04.070] and 2,4-dimethylphenol [FL-no: 04.066] 
negative results were observed in bacterial gene mutation assays (Zeiger et al., 1992; Mortelmans et 
al., 1986; Pool & Lin, 1982). All other results observed in several assays with these two and seven 
further candidate substances for which data were available were negative. However, these data were of 
limited or insufficient quality and the validity of the studies could not be evaluated. 
With supporting substances positive and negative results were obtained in in vitro tests. 
2-Methylphenol [FL-no: 04.027], 3-methylphenol [FL-no: 04.026], 4-methylphenol [FL-no: 04.028], 
2-methoxyphenol [FL-no: 04.005] and 2,6-dimethoxyphenol [FL-no: 04.036] did not induce gene 
mutations in bacterial assays of acceptable quality (Haworth et al., 1983; Pool & Lin, 1982). The 
validity of a positive result observed with 2-methylphenol FL-no: 04.027] in bacteria (Claxton, 1985) 
cannot be evaluated. 
2,6-Dimethylphenol [FL-no: 04.042] induced chromosomal aberrations in mammalian cells in the 
presence of S9 while the result was negative in the absence of metabolic activation (Völkner, 1994). 
The in vitro genotoxic potential of 2,6-dimethylphenol does not give rise to concern with respect to 
other alkylated phenols in this FGE, as they are alkyl substituted in either m- or p-positions. Phenols, 
substituted in m- or p-position are expected to be metabolised differently from 2,6-dimethylphenol. 
2-Methoxyphenol [FL-no: 04.005], 2-methoxy-4-methylphenol [FL-no: 04.007], 2-methylphenol [FL-
no: 04.027] and a mixture of 2-methylphenol [FL-no: 04.027], 3-methylphenol [FL-no: 04.026] and 4-
methylphenol [FL-no: 04.028] induced sister chromatid exchanges in human lymphocytes or CHO 
cells. In most cases the effects were observed in the presence and absence of metabolic activation. 
The mixture of 2-methylphenol [FL-no: 04.027], 3-methylphenol [FL-no: 04.026] and 4-methylphenol 
[FL-no: 04.028] resulted in an equivocal response in a UDS assay (Myhr & Brusick, 1980) while 
induction of UDS was observed with 4-methylphenol [FL-no: 04.028] in another in vitro study 
(Crowley & Margard, 1978). 
All other results observed in several in vitro assays with these and the remaining supporting 
substances were negative, however, these data were of limited or insufficient quality and the validity 
of the studies could not be evaluated. 
With the supporting substances 2-methylphenol [FL-no: 04.027], 3-methylphenol [FL-no: 04.026] and 
4-methylphenol [FL-no: 04.028] negative results were obtained in in vivo SCE assays (Cheng & 
Kligerman, 1984). However, these data were of limited quality. 3-Methylphenol [FL-no: 04.026] did 
not induce chromosomal aberrations in mice (Ivett et al., 1989). However, the validity of the result 
could not be evaluated as the study was inadequately reported. 2-Methylphenol [FL-no: 04.027] and 
carvacrol [FL-no: 04.031] did not induce mutations in Drosophila (Sernau, 1989; Kono et al., 1995). 
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Overall, the available genotoxicity data on the supporting substances would not preclude evaluation of 
the candidate substances through the Procedure. One of the candidate substances, 3,4-
methylenedioxyphenol [FL-no: 04.080], was reported to have genotoxic potential in vitro. In vivo 
studies were not available for this candidate substance. Therefore, the Panel decided that the Procedure 
could not be applied to this candidate substance until adequate genotoxicity data become available. 
The genotoxicity data are summarised in Annex IV, Table IV.4 and IV.5 
9. Conclusions 
The 28 candidate substances are ring substituted phenolic substances belonging to chemical groups 21 
and 25. 
Two of the candidate substances have a chiral centre, the commercial product of both substances are 
the racemate. 
Twenty-five of the flavouring substances are classified into structural class I and three are classified 
into structural class II [FL-no: 04.091, 04.092 and 07.234]. 
Twenty-two of the flavouring substances in the present group have been reported to occur naturally in 
a wide range of food items. 
According to the default MSDI approach, the 28 flavouring substances in this group have intakes in 
Europe from 0.001 to 610 microgram/capita/day, which are all below the thresholds of concern for 
their respective class of 1800 microgram/person/day for structural class I or 540 
microgram/person/day for structural class II substances. 
One of the flavourings substances, 3,4-methylenedioxyphenol [FL-no: 04.080], was reported to have a 
genotoxic potential in vitro, while in vivo studies were not available for this candidate substance. 
Therefore, the Panel decided that the Procedure could not be applied to this candidate substance until 
adequate genotoxicity data become available. The genotoxicity data available did not preclude an 
evaluation of the other 27 candidate flavouring substances in this Flavouring Group Evaluation 
through the Procedure. 
The candidate substances in this group are conjugated with glucuronic acid or sulphate very efficiently 
and these pathways are not easily saturated. At high dose levels reactive metabolites (quinones, 
catechols, quinone methides) may be formed, but it is not expected that, at the levels of intake from 
the use as flavouring substances, the formation of these metabolites would overwhelm detoxication 
capacity through conjugation with sulphate, glucuronic acid or in particular glutathione. Thus, it is 
concluded that all 27 candidate substances in this group, which have been evaluated using the 
Procedure, may be expected to be metabolised to innocuous products at the estimated levels of intake, 
based on the MSDI approach. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present flavouring group evaluation using the Procedure. 
It was considered that on the basis of the default MSDI approach the 27 candidate substances 
evaluated through the Procedure would not give rise to safety concerns at the estimated levels of 
intake arising from their use as flavouring substances. The total combined intake of the candidate and 
supporting substances belonging to structural class I is approximately 3900 microgram/capita/day, 
which exceeds the threshold of concern for a compound belonging to structural class I of 1800 
microgram/person/day. The main contribution to the MSDI of 3900 microgram/capita/day originates 
from one supporting substance, 4-(p-hydroxyphenyl)butan-2-one [FL-no: 07.055], for which the 
estimated daily per capita intake is 2400 microgram. For this supporting substance a 13 week study 
provides a NOAEL of 100 mg/kg bw/day which gives a margin of safety of 2500 to the MSDI value. 
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The estimated intakes for the 24 candidate substances evaluated through the Procedure and belonging 
to structural class I, range from 74 to 35000 microgram/person/day based on the mTAMDI. The 
mTAMDI is above the threshold of concern of 1800 microgram/person/day for two of the candidate 
substances [FL-no: 08.134 and 09.946].  
The estimated intakes of the three substances evaluated through the Procedure and belonging to 
structural class II, are 420 microgram/person/day based on the mTAMDI, which is below the threshold 
of concern for structural class II substances of 540 microgram/person/day. 
Thus, for two candidate substances [FL-no: 08.134 and 09.946], for which the mTAMDI is above the 
threshold,  further information is required. This would include more reliable intake data and then, if 
required, additional toxicological data. 
The 25 substances which have mTAMDI intake estimates below the threshold of concern for their 
structural class are also expected to be metabolised to innocuous products. 
In order to determine whether the conclusion for the 27 candidate substances evaluated using the 
Procedure can be applied to the materials of commerce, it is necessary to consider the available 
specifications. Adequate specifications including complete purity criteria and identity tests for the 
materials of commerce have been provided for all 27 flavouring substances evaluated through the 
Procedure. 
Thus, the Panel concluded that for one candidate substance [FL-no: 04.080] additional genotoxicity 
data are required and that the remaining 27 candidate substances would present “no safety concern at 
the estimated level of intakes, based on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 22, REVISION 1 
Table 1: Specification Summary of the Substances in the FGE.22Rev1 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
04.020 
 
3,5-Dimethylphenol OH  
538 
108-68-9 
Solid 
C8H10O 
122.17 
Slightly soluble 
Freely soluble 
220 
63 
MS 
95 % 
n.a. 
n.a. 
 
 
04.021 
 
3-Ethylphenol OH
 
 
549 
620-17-7 
Liquid 
C8H10O 
122.17 
Slightly soluble 
Freely soluble 
217 
 
MS 
95 % 
1.529-1.535 
1.019-1.025 
 
 
04.061 
 
2,6-Dimethoxy-4-vinylphenol O
OH
O
 
11229 
28343-22-8 
Solid 
C10H12O3 
180.20 
Practically insoluble 
or insoluble 
Freely soluble 
314 
135 
NMR 
95 % 
n.a. 
n.a. 
 
 
04.065 
 
2,3-Dimethylphenol OH  
11258 
526-75-0 
Solid 
C8H10O 
122.17 
Slightly soluble 
Freely soluble 
218 
76 
MS 
95 % 
n.a. 
n.a. 
 
 
04.066 
 
2,4-Dimethylphenol OH
 
 
11259 
105-67-9 
Solid 
C8H10O 
122.17 
Very slightly soluble 
Freely soluble 
210 
26 
MS 
95 % 
n.a. 
n.a. 
 
 
04.070 
 
2-Ethylphenol OH
 
 
11232 
90-00-6 
Liquid 
C8H10O 
122.17 
Slightly soluble 
Freely soluble 
204 
 
MS 
95 % 
1.534-1.540 
1.020-1.026 
 
 
04.072 
 
3-Isopropylphenol OH  
 
618-45-1 
Solid 
C9H12O 
136.19 
Practically insoluble 
or insoluble 
Freely soluble 
228 
26 
MS 
95 % 
n.a. 
n.a. 
 
 
04.073 
 
4-Isopropylphenol 
OH
 
 
 
99-89-8 
Solid 
C9H12O 
136.19 
Practically insoluble 
or insoluble 
Freely soluble 
223 
64 
MS 
95 % 
n.a. 
n.a. 
 
 
04.076 
 
3-Methoxyphenol 
OH
O
 
 
150-19-6 
Liquid 
C7H8O2 
124.14 
Slightly soluble 
Freely soluble 
244 
 
MS 
95 % 
1.547-1.553 
1.063-1.069 
 
 
04.077 
 
4-Methoxyphenol 
O OH
 
 
11241 
150-76-5 
Solid 
C7H8O2 
124.14 
Slightly soluble 
Freely soluble 
243 
57 
MS 
n.a. 
n.a. 
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Table 1: Specification Summary of the Substances in the FGE.22Rev1 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
95 % 
04.078 
 
5-Methyl-2-(tert-butyl)phenol OH
 
 
 
88-60-8 
Solid 
C11H16O 
164.25 
Practically insoluble 
or insoluble 
Freely soluble 
244 
22 
MS 
95 % 
n.a. 
n.a. 
 
 
04.080 
 
3,4-Methylenedioxyphenol OH
O
O
 
 
 
533-31-3 
Solid 
C7H6O3 
138.12 
Slightly soluble 
Freely soluble 
115 (3 hPa) 
63 
MS 
95 % 
n.a. 
n.a. 
 
 
04.091 
 
Ethyl 4-hydroxybenzyl ether 
OH
O
 
 
 
57726-26-8 
Solid 
C9H12O2 
152.19 
Practically insoluble 
or insoluble 
Freely soluble 
105 (1 hPa) 
53 
MS 
95 % 
n.a. 
n.a. 
 
 
04.092 
 
4-Hydroxybenzyl methyl ether 
OH
O
 
 
 
5355-17-9 
Solid 
C8H10O2 
138.17 
Practically insoluble 
or insoluble 
Freely soluble 
175 
82 
MS 
95 % 
n.a. 
n.a. 
 
 
04.095 
 
2,4,6-Trimethylphenol 
OH
 
4329 
 
527-60-6 
Solid 
C9H12O 
136.19 
Practically insoluble 
or insoluble 
Freely soluble 
221 
70 
MS 
95 % 
n.a. 
n.a. 
 
 
07.142 
 
Acetovanillone 
O
OH
O
 
11035 
498-02-2 
Solid 
C9H10O3 
166.18 
Slightly soluble 
Freely soluble 
297 
115 
MS 
95 % 
n.a. 
n.a. 
 
 
07.154 
 
1-(3,5-Dimethoxy-4-
hydroxyphenyl)propan-1-one 
O
OH
O
O  
11106 
5650-43-1 
Solid 
C11H14O4 
210.23 
Practically insoluble 
or insoluble 
Freely soluble 
394 
109 
NMR 
95 % 
n.a. 
n.a. 
 
 
07.164 
 
4-Hydroxy-3,5-dimethoxyacetophenone 
O
OH
O
O  
11105 
2478-38-8 
Solid 
C10H12O4 
196.20 
Practically insoluble 
or insoluble 
Freely soluble 
371 
122 
MS 
95 % 
n.a. 
n.a. 
 
 
07.234 
 
5-Paradol 
O
HO
O
 
 
 
 
Solid 
C17H26O3 
278.39 
Practically insoluble 
or insoluble 
Freely soluble 
168 (0.1 hPa) 
31 
MS 
95 % 
n.a. 
n.a. 
 
Register name to be changed 
to 1-(4-Hydroxy-3-
methoxyphenyl)-3-
decanone; CASrn: 27113-
22-0 and EINECS: 248-208-
1. 
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Table 1: Specification Summary of the Substances in the FGE.22Rev1 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
07.243 
 
4-Hydroxyacetophenone 
OH
O 4330 
 
99-93-4 
Solid 
C8H8O2 
136.15 
Practically insoluble 
or insoluble 
Freely soluble 
286 
110 
MS 
95 % 
n.a. 
n.a. 
 
 
08.134 
- 
Nibovan 
OH
O
HO
OH
O
4660 
- 
55-10-7 
Solid 
C9H10O5 
198.17 
Slightly soluble 
Freely soluble 
n.a. 
126.7 
IR NMR MS 
96 % 
n.a. 
n.a. 
 
Racemate. 
Register name to be changed 
to: 4-Hydroxy-3-methoxy-
mandelic acid. 
09.253 
 
2-Isopropyl-5-methylphenyl acetate 
O
O  
2308 
528-79-0 
Solid 
C12H16O2 
192.26 
Practically insoluble 
or insoluble 
Freely soluble 
243 
30 
MS 
95 % 
1.531-1.537 
n.a. 
 
 
09.337 
 
Carvacryl acetate 
O O
 
 
 
6380-28-5 
Solid 
C12H16O2 
192.26 
Practically insoluble 
or insoluble 
Freely soluble 
245 
30 
MS 
95 % 
1.489-1.495 
n.a. 
 
 
09.893 
 
2-Isopropyl-5-methylphenyl formate O O  
 
 
Solid 
C11H14O2 
178.23 
Practically insoluble 
or insoluble 
Freely soluble 
286 
41 
NMR 
95 % 
n.a. 
n.a. 
 
CASrn 406700-80-9 to be 
introduced in the Register 
(EFFA, 2004g). 
09.943 
- 
Guaiacol propionate 
O
O
O 4609 
- 
7598-60-9 
Liquid 
C10H12O3 
180.2 
Slightly soluble 
Soluble 
118 (8.3 Torr) 
n.a. 
NMR MS 
99 % 
1.5276-
1.5376 
1.0926-
1.1026 
 
 
09.944 
- 
Guaiacol butyrate 
O
O
O 4607 
- 
4112-92-9 
Liquid 
C11H14O3 
194.23 
Slightly soluble 
Soluble 
96-97(1.5 Torr) 
n.a. 
NMR MS 
99 % 
1.522-1.532 
1.0644-
1.0744 
 
 
09.945 
- 
Guaiacol isobutyrate 
O
O
O 4608 
- 
723759-62-
4 
Liquid 
C11H14O3 
194.23 
Slightly soluble 
Soluble 
78-80(0.75Torr) 
n.a. 
NMR MS 
99 % 
1.5175-
1.5275 
1.0559-
1.0659 
 
 
09.946 
- 
Dihydrogalangal acetate 
O
OO
O 4555 
- 
129319-15-
9 
Solid 
C13H16O4 
236 
Insoluble 
Slightly soluble 
n.a. 
41.5-43.5 
NMR MS 
99.5 % 
n.a. 
n.a. 
 
Racemate. 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95%  ethanol, if not otherwise stated. 
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3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2A: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
04.020 
 
3,5-Dimethylphenol OH 0.037 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.021 
 
3-Ethylphenol OH 0.073 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.061 
 
2,6-Dimethoxy-4-vinylphenol O
OH
O
1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.065 
 
2,3-Dimethylphenol OH
 
0.013 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.066 
 
2,4-Dimethylphenol OH 0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.070 
 
2-Ethylphenol OH 0.037 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.072 
 
3-Isopropylphenol OH
 
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.073 
 
4-Isopropylphenol 
OH
0.24 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.076 
 
3-Methoxyphenol 
OH
O
0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.077 
 
4-Methoxyphenol 
O OH
0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.078 
 
5-Methyl-2-(tert-butyl)phenol OH 0.061 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.095 
 
2,4,6-Trimethylphenol 
OH
0.0097 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
07.142 
 
Acetovanillone 
O
OH
O
2.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
07.154 
 
1-(3,5-Dimethoxy-4-
hydroxyphenyl)propan-1-one 
O
OH
O
O 0.026 
 
Class I 
A3: Intake below threshold 
4) 6)  
07.164 
 
4-Hydroxy-3,5-
dimethoxyacetophenone 
O
OH
O
O 0.24 
 
Class I 
A3: Intake below threshold 
4) 6)  
07.243 
 
4-Hydroxyacetophenone 
OH
O 0.016 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.134 
- 
Nibovan 
OH
O
HO
OH
O
120 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.253 
 
2-Isopropyl-5-methylphenyl 
acetate 
O
O 1.1 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.337 
 
Carvacryl acetate 
O O
0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.893 
 
2-Isopropyl-5-methylphenyl 
formate 
O O 0.52 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.943 
- 
Guaiacol propionate 
O
O
O 43 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
09.944 
- 
Guaiacol butyrate 
O
O
O 43 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.945 
- 
Guaiacol isobutyrate 
O
O
O 43 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.946 
- 
Dihydrogalangal acetate 
O
OO
O 610 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.080 
 
3,4-Methylenedioxyphenol OH
O
O 1.7 
 
Class I 
No evaluation 
  a) 
04.091 
 
Ethyl 4-hydroxybenzyl ether 
OH
O
0.0012 
 
Class II 
A3: Intake below threshold 
4) 6)  
04.092 
 
4-Hydroxybenzyl methyl ether 
OH
O 0.61 
 
Class II 
A3: Intake below threshold 
4) 6)  
07.234 
 
5-Paradol 
O
HO
O 0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800, Class II = 540, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach.) 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
a) Evaluation deferred pending further genotoxicity data. 
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TABLE 2B: EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS  
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
Non-
register 
Dihydrogalangal 
OH
HO
Not evaluated as flavouring substance  Not in Register 
04.005 2-Methoxyphenol 
713 
OH
O
 
 
No safety concern a) 
Category B b) 
 
Class I 
A3: Intake below threshold 
 
04.006 Thymol 
709 
OH  
 
No safety concern a) 
Category B b) 
 
Class I 
A3: Intake below threshold 
 
04.031 Carvacrol 
710 
OH  
 
No safety concern a) 
Category B b) 
 
Class I 
A3: Intake below threshold 
 
08.001 Formic acid 
79 
OHO  Category 1 c) 
No safety concern d) 
Deleted b) 
 
Class I 
A3: Intake below threshold 
 
08.002 Acetic acid 
81 
O
OH  
Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.003 Propionic acid 
84 
OH
O  
Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.005 Butyric acid 
87 
OH
O
 
Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.006 2-Methylpropionic acid 
253 
O
OH
 
Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs 
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4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (JECFA, 2001a). 
b) (CoE, 1992). 
c) (SCF, 1995). 
d) (JECFA, 1999b). 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
04.005 2-Methoxyphenol 
OH
O
2532 
173 
90-05-1 
713 
JECFA specification (JECFA, 
2000d) 
44  
No safety concern a) 
Category B b) 
 
04.006 Thymol 
OH
3066 
174 
89-83-8 
709 
JECFA specification (JECFA, 
2000d) 
51  
No safety concern a) 
Category B b) 
 
04.007 2-Methoxy-4-methylphenol 
OH
O
2671 
175 
93-51-6 
715 
JECFA specification (JECFA, 
2000d) 
31  
No safety concern a) 
Category B b) 
 
04.008 4-Ethylguaiacol 
OH
O
2436 
176 
2785-89-9 
716 
JECFA specification (JECFA, 
2000d) 
6.9  
No safety concern a) 
Category B b) 
 
04.009 2-Methoxy-4-vinylphenol 
OH
O
2675 
177 
7786-61-0 
725 
JECFA specification (JECFA, 
2000d) 
2.6  
No safety concern a) 
Deleted b) 
 
04.019 2,5-Dimethylphenol 
OH
3595 
537 
95-87-4 
706 
JECFA specification (JECFA, 
2000d) 
0.49  
No safety concern a) 
Deleted b) 
 
04.022 4-Ethylphenol 
OH
 
3156 
550 
123-07-9 
694 
JECFA specification (JECFA, 
2000d) 
3.5  
No safety concern a) 
Category B b) 
 
04.026 3-Methylphenol 
OH
3530 
617 
108-39-4 
692 
JECFA specification (JECFA, 
2000d) 
0.12  
No safety concern a) 
Category A b) 
 
04.027 2-Methylphenol 
OH
3480 
618 
95-48-7 
691 
JECFA specification (JECFA, 
2000d) 
250  
No safety concern a) 
Category A b) 
 
04.028 4-Methylphenol 
OH
 
2337 
619 
106-44-5 
693 
JECFA specification (JECFA, 
2000d) 
0.97  
No safety concern a) 
Category A b) 
 
04.031 Carvacrol 
OH
2245 
2055 
499-75-2 
710 
JECFA specification (JECFA, 
2000d) 
14  
No safety concern a) 
Category B b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
04.036 2,6-Dimethoxyphenol 
OH
O
O 3137 
2233 
91-10-1 
721 
JECFA specification (JECFA, 
2000d) 
5.4  
No safety concern a) 
Category B b) 
 
04.037 4-Ethoxyphenol 
OHO
 
3695 
2258 
622-62-8 
720 
JECFA specification (JECFA, 
2001c) 
0.37  
No safety concern a) 
Category B b) 
 
04.042 2,6-Dimethylphenol 
OH
3249 
11261 
576-26-1 
707 
JECFA specification (JECFA, 
2000d) 
1.7  
No safety concern a) 
 
 
04.044 2-Isopropylphenol 
OH
3461 
11234 
88-69-7 
697 
JECFA specification (JECFA, 
2000d) 
14  
No safety concern a) 
 
 
04.045 2-(Ethoxymethyl)phenol 
OH
O
3485 
11905 
20920-83-6 
714 
JECFA specification (JECFA, 
2000d) 
1.5  
No safety concern a) 
 
 
04.046 2-Propylphenol 
OH
3522 
11908 
644-35-9 
695 
JECFA specification (JECFA, 
2000d) 
0.12  
No safety concern a) 
 
 
04.048 3,4-Dimethylphenol 
OH
3596 
11262 
95-65-8 
708 
JECFA specification (JECFA, 
2000d) 
5.7  
No safety concern a) 
 
 
04.049 2-Methoxy-4-propylphenol 
OH
O
3598 
 
2785-87-7 
717 
JECFA specification (JECFA, 
2000d) 
180  
No safety concern a) 
 
 
04.050 4-Propylphenol 
OH
 
3649 
 
645-56-7 
696 
JECFA specification (JECFA, 
2000d) 
0.049  
No safety concern a) 
 
 
04.051 4-Allyl-2,6-dimethoxyphenol 
OH
O
O 3655 
11214 
6627-88-9 
726 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern a) 
 
 
04.052 4-Ethyl-2,6-dimethoxyphenol 
OH
O
O 3671 
11231 
14059-92-8 
723 
JECFA specification (JECFA, 
2001c) 
1.3  
No safety concern a) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
04.053 4-Methyl-2,6-dimethoxyphenol 
OH
O
O 3704 
 
6638-05-7 
722 
JECFA specification (JECFA, 
2000d) 
0.054  
No safety concern a) 
 
 
04.056 2,6-Dimethoxy-4-propylphenol 
OH
O
O 3729 
 
6766-82-1 
724 
JECFA specification (JECFA, 
2001c) 
0.061  
No safety concern a) 
 
 
04.057 4-Vinylphenol 
OH
 
3739 
11257 
2628-17-3 
711 
JECFA specification (JECFA, 
2001c) 
0.12  
No safety concern a) 
 
 
04.064 4-(1,1-Dimethylethyl)phenol 
OH
 
3918 
 
98-54-4 
733 
JECFA specification (JECFA, 
2000d) 
0.012  
No safety concern a) 
 
 
04.085 2,3,6-Trimethylphenol 
OH
3963 
 
2416-94-6 
737 
JECFA specification (JECFA, 
2003b) 
0.24  
No safety concern a) 
 
 
07.005 Vanillyl acetone 
O
OH
O 3124 
139 
122-48-5 
730 
JECFA specification (JECFA, 
2000d) 
34  
No safety concern a) 
Category B b) 
 
07.055 4-(p-Hydroxyphenyl)butan-2-one 
OH
O
2588 
755 
5471-51-2 
728 
JECFA specification (JECFA, 
2000d) 
2400  
No safety concern a) 
Category A b) 
 
07.124 2-Hydroxyacetophenone 
OH
O 3548 
11784 
118-93-4 
727 
JECFA specification (JECFA, 
2000d) 
0.12  
No safety concern a) 
 
 
07.135 2,4-Dihydroxyacetophenone 
(OH)2
O
 
3662 
11884 
28631-86-9 
729 
JECFA specification (JECFA, 
2002d) 
0.012  
No safety concern a) 
 
JECFA evaluated a 
mixture of 
dihydroxyacetophenone
s 
09.036 p-Tolyl acetate 
O
O 3073 
226 
140-39-6 
699 
JECFA specification (JECFA, 
2000d) 
0.047  
No safety concern a) 
Category B b) 
 
09.102 p-Tolyl dodecanoate O
O  
3076 
378 
10024-57-4 
704 
JECFA specification (JECFA, 
2003b) 
0.24  
No safety concern a) 
Category B b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.174 2-Methoxyphenyl acetate 
O
O
O 3687 
552 
613-70-7 
718 
JECFA specification (JECFA, 
2000d) 
0.012  
No safety concern a) 
Category B b) 
 
09.228 o-Tolyl acetate 
O
O
3072 
2078 
533-18-6 
698 
JECFA specification (JECFA, 
2001c) 
0.12  
No safety concern a) 
Category B b) 
 
09.288 4-(4-Acetoxyphenyl)butan-2-one O
O
O
3652 
 
3572-06-3 
731 
JECFA specification (JECFA, 
2000d) 
0.12  
No safety concern a) 
 
 
09.301 p-Tolyl octanoate O
O  
3733 
 
59558-23-5 
703 
JECFA specification (JECFA, 
2000d) 
0.024  
No safety concern a) 
 
 
09.429 p-Tolyl isobutyrate 
O
O
3075 
304 
103-93-5 
701 
JECFA specification (JECFA, 
2000d) 
0.037  
No safety concern a) 
Category B b) 
 
09.480 o-Tolyl isobutyrate 
O
O
3753 
681 
36438-54-7 
700 
JECFA specification (JECFA, 
2000d) 
0.024  
No safety concern a) 
Category B b) 
 
09.518 4-Methylphenyl isovalerate O
O  
3387 
10545 
55066-56-3 
702 
JECFA specification (JECFA, 
2000d) 
0.37  
No safety concern a) 
 
 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2001a). 
b) (CoE, 1992). 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation(EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products8 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous9 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
8 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
9 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for the 23 candidate substances in the 
present flavouring group (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.22 (EFFA, 2004g; 
EFFA, 2007a; Flavour Industry, 2009k). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
04.020 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.021 0,5 
2 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.061 0,5 
2,5 
0,2 
1 
0,2 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.065 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.066 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.070 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.072 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.073 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.076 0,5 
2,5 
0,2 
1 
0,2 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.22 (EFFA, 2004g; 
EFFA, 2007a; Flavour Industry, 2009k). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
04.077 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.078 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.080 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.091 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,3 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.092 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
04.095 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
07.142 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
07.154 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
07.164 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
07.234 0,5 
2 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
07.243 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
08.134 10 
50 
- 
- 
10 
100 
- 
- 
- 
- 
10 
20 
10 
20 
10 
20 
- 
- 
- 
- 
- 
- 
- 
- 
10 
20 
- 
- 
5 
10 
10 
20 
- 
- 
20 
50 
09.253 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
09.337 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
09.893 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
09.943 - 
- 
- 
- 
0,1 
5 
- 
- 
- 
- 
0,2 
5 
0,2 
5 
0,2 
5 
- 
- 
- 
- 
- 
- 
0,1 
5 
- 
- 
- 
- 
0,1 
5 
0,2 
5 
0,3 
10 
0,2 
5 
09.944 - 
- 
- 
- 
0,1 
5 
- 
- 
- 
- 
0,2 
5 
0,2 
5 
0,2 
5 
- 
- 
- 
- 
- 
- 
0,1 
5 
- 
- 
- 
- 
0,1 
5 
0,2 
5 
0,3 
10 
0,2 
5 
09.945 - 
- 
- 
- 
0,1 
5 
- 
- 
- 
- 
0,2 
5 
0,2 
5 
0,2 
5 
- 
- 
- 
- 
- 
- 
0,1 
5 
- 
- 
- 
- 
0,1 
5 
0,2 
5 
0,3 
10 
0,2 
5 
09.946 - 
- 
- 
- 
- 
- 
- 
- 
- 
- 
25 
500 
- 
- 
- 
- 
100 
500 
100 
500 
- 
- 
0,1 
5 
500 
1000 
- 
- 
0,5 
5 
25 
100 
500 
1000 
- 
- 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
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The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
 
The mTAMDI values are presented for each of the 28 flavouring substances in the present flavouring group, 
for which Industry has provided use and use levels (EFFA, 2004g; Flavour Industry, 2009k). The mTAMDI 
values are only given for normal (average) use levels and are presented as a range corresponding to the 
lowest and highest normal use level within a food category (see Table II.2.3). 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
04.020 3,5-Dimethylphenol 420 Class I 1800 
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TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
04.021 3-Ethylphenol 420 Class I 1800 
04.061 2,6-Dimethoxy-4-vinylphenol 420 Class I 1800 
04.065 2,3-Dimethylphenol 420 Class I 1800 
04.066 2,4-Dimethylphenol 420 Class I 1800 
04.070 2-Ethylphenol 420 Class I 1800 
04.072 3-Isopropylphenol 420 Class I 1800 
04.073 4-Isopropylphenol 420 Class I 1800 
04.076 3-Methoxyphenol 420 Class I 1800 
04.077 4-Methoxyphenol 420 Class I 1800 
04.078 5-Methyl-2-(tert-butyl)phenol 420 Class I 1800 
04.095 2,4,6-Trimethylphenol 420 Class I 1800 
07.142 Acetovanillone 420 Class I 1800 
07.154 1-(3,5-Dimethoxy-4-hydroxyphenyl)propan-1-one 420 Class I 1800 
07.164 4-Hydroxy-3,5-dimethoxyacetophenone 1600 Class I 1800 
07.243 4-Hydroxyacetophenone 1600 Class I 1800 
08.134 Nibovan 5000 Class I 1800 
09.253 2-Isopropyl-5-methylphenyl acetate 420 Class I 1800 
09.337 Carvacryl acetate 420 Class I 1800 
09.893 2-Isopropyl-5-methylphenyl formate 420 Class I 1800 
09.943 Guaiacol propionate 74 Class I 1800 
09.944 Guaiacol butyrate 74 Class I 1800 
09.945 Guaiacol isobutyrate 74 Class I 1800 
09.946 Dihydrogalangal acetate 35000 Class I 1800 
04.080 3,4-Methylenedioxyphenol 420 Class I 1800 
04.091 Ethyl 4-hydroxybenzyl ether 420 Class II 540 
04.092 4-Hydroxybenzyl methyl ether 420 Class II 540 
07.234 5-Paradol 420 Class II 540 
 
Flavouring Group Evaluation 22, Revision 1
 
 
39 EFSA Journal 2011; 9(5):1990 
ANNEX III: METABOLISM 
III.1. Introduction 
The candidate flavouring substances in this group are ring-substituted phenols and esters thereof. Twenty of 
the substances [FL-no: 04.020, 04.021, 04.061, 04.065, 04.066, 04.070, 04.072, 04.073, 04.076, 04.077, 
04.078, 04.080, 04.091, 04.092, 04.095, 07.142, 07.154, 07.164, 07.243 and 07.234] are phenols, which bear 
one or more substituents. These substituents include methyl, ethyl, vinyl, isopropyl, tert-butyl, methoxy, 
methyl- and ethyl-benzyl ether, 1-acetyl, 1-propionyl or decan-3-one groups. One of these phenols [FL-no: 
04.080] bears a methylenedioxy-ring. 
Six other substances in this group are esters: the formate and acetate of thymol (= 2-isopropyl-5-
methylphenol) [FL-no: 09.253 and 09.893], the acetate of carvacrol (= 2-methyl-5-isopropylphenol) [FL-no: 
09.337] and the propionate-, butyrate- and isobutyrate esters of guaiacol (= 2-methoxyphenol) [FL no: 
09.943, 09.444 and 09.945]. One substance (dihydrogalangal acetate ) [FL no: 09.946] is a diacetate ester of 
dihydrogalangal (= 1-(4-(hydroxymethyl)phenyl)-propan-1-ol), which is not in the Register. 
 
The remaining substance (nibovan) [FL no: 08.134] bears as a ring substituent 2-hydroxyacetic acid. 
A number of structurally related phenolic supporting substances have been evaluated previously by the 
JECFA (JECFA, 2001b). 
III.2. Absorption, Distribution and Elimination 
General data 
No detailed absorption and distribution studies for the candidate flavouring substances in this group have 
been submitted. However, uptake, metabolism and elimination of phenols have been studied quite 
extensively, and from the high fractions of the dose that can be found in urine usually within 24 hours, it 
must be concluded that in general these substances are readily and almost completely absorbed and excreted 
via urine. However, data cited by Williams may indicate that the intestinal absorption of carvacrol may be 
considerably less than for other phenols (Williams, 1959a). 
It is believed that p-cresol, found in serum from healthy human volunteers (0.23 ± 0.17 mg/100 ml), is also 
formed via bacterial degradation of proteins in the intestinal lumen (Wengle & Hellström, 1972). In addition, 
in an extensive review on biotransformations the natural occurrence of p-ethylphenol, p-cresol, catechol and 
quinol in urine from various mammals, including humans has been reported (Williams, 1959a). 
Candidate substances 
4-Methoxyphenol [FL-no: 04.077] 
Female rabbits (2.5 to 3.5 kg) were administered a suspension of 0.7 g p-hydroxy-anisole (= 4-
methoxyphenol) once via oral gavage. The mean quantity of the administered dose excreted via the urine 
within 24 hours following administration was 82 % (Bray et al., 1955), which indicates rapid absorption and 
elimination. 
2,4-Dimethylphenol [FL-no: 04.066] 
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2,4-Dimethylphenol (2,4-DMP) was administered to male Sprague-Dawley rats by constant intravenous 
infusion at 17 mg/hour for six hours, intravenous bolus injection at 30 mg/kg bw, or intraperitoneal bolus 
injection at 30 mg/kg bw. Blood samples were collected at the end of the 6 hours infusion period, at 5, 10, 
20, 30 and 60 min after the intravenous bolus injection or at 30 min after the intraperitoneal bolus injection 
for at least 3 animals per treatment / time point. At the same time points brain, liver and fat tissue samples 
were collected. 2,4-DMP distributed rapidly in the brain and liver following an intravenous bolus injection 
reaching peak concentrations in these tissues and plasma by the first measurement point at 5 minutes and 
declining rapidly over the next 5 to 30 minute intervals. Plasma, liver and fat concentrations of the parent 
compound were undetectable at 60 minutes; however, 2,4-DMP was detectable in brain tissue at 60 minutes 
at about 10 % of its value measured at 5 minutes. Also after intravenous infusion for six hours 2,4-DMP 
showed higher tissue than plasma-concentrations (ratios about 2.8, 1.4 and 2.1 for brain, liver and fat, 
respectively). The authors concluded that, “The probability of accumulation of 2,4-DMP in brain, liver and 
fat appears to be minimal, due to rapid metabolism” (Kaka et al., 1982) 
III.3. Metabolism 
General data 
Various ring-substituted phenols were administered at dose levels of 150 - 450 mg/kg bw via gavage to 
fasted rabbits and urine samples were collected until renal excretion had been completed (usually between 6-
16 hours after administration of the substance) (Bray et al., 1952d). In some of the studies (see below) the 
phenols were given together with sodium sulphite or L-cysteine, which served as "sulphate donors" (in 
various amounts at various time points). Glucuronic acid conjugation of phenol appeared to be proportional 
to the administered dose. The rate constants for glucuronidation were not affected by the co-administration 
of a "sulphate donor". In addition, ring substitution did not affect the rate constant for glucuronidation, 
unless two methyl groups were present in ortho-position (i.e. 2,6-dimethylphenol) or a ring substituent 
heavier than ~ 35 D (chlorine) was present at para-position. In these cases a lower rate constant for 
glucuronidation was observed.  
The same authors also studied rates of sulphation and the dependence of this conjugation reaction upon 
availability of sulphate (as sulphite or L-cycteine). In fasted rabbits with various phenols given at 250 mg/kg 
bw by gavage, the sulphate conjugation ranged from 7 to 28 % of the dose excreted via the urine in control 
animals. When phenols were given in combination with either sulphite or L-cysteine, urinary excretion of 
sulphate conjugates ranged from 22 – 75 %. The rate of sulphate conjugation was not influenced in a 
significant way by the nature of the ring substituents. The authors concluded that sulphate conjugation was 
dependent upon sulphate availability (Bray et al., 1952c). 
Ester hydrolysis 
Limited data have been submitted to support ester hydrolysis of the candidate esters. 60 % of o-cresyl acetate 
was hydrolysed in vitro following incubation with pancreatin for two hours at 37°C and pH 7.5 
(Grundschober, 1977). Methyl salicylate has been shown to be hydrolysed in vivo in rats, dogs and humans 
(Davison et al., 1961). A male human volunteer was orally administered one capsule of 90 mg phenyl 
salicylate per hour for 8 hours. Urine was collected for 72 hours beginning with the first dose, and 
fractionated into 8-hours collection periods. Analysis of total urinary phenol showed a 472 mg/l peak during 
the second 8 hours collection period. The level of free urinary phenol peaked at 25 mg/l during the same 
period. Approximately sixty hours after the first dose, both total and free urinary phenol levels returned to 
baseline levels (7 ppm and 1 ppm, respectively). Based on the presented data, for the phenol moiety a total 
urinary recovery of 130 % could be calculated after subtraction of the baseline phenol excretion (Fishbeck et 
al., 1975). From the urinary excretion of phenol, it can be concluded that phenyl salicylate is probably 
completely hydrolysed, either in the GI-tract or after absorption.  
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Although these data are fairly limited, it is expected that the esters of the three alkyl-substituted phenolic 
candidate flavouring substances undergo ester hydrolysis in vivo. The hydrolysis products are formic and 
acetic acid from [FL-no: 09.893] and [FL-no: 09.253 and 09.337], respectively. These acids have previously 
been evaluated (SCF, 2002d; SCF, 2002e). The alcohols released after ester hydrolysis are 2-methyl-5-
isopropylphenol (= carvacrol) and 5-methyl-2-isopropylphenol (= thymol) for [FL-no: 09.337] and [FL-no: 
09.893 and 09.253], respectively. These two alcohols have no special structural features as compared to the 
other candidate phenols in this FGE. Ester hydrolysis may also be expected for [FL-no: 09.943, 09.944, 
09.945 and 09.946] which would yield the free phenolic substances guaiacol [FL-no: 04.005] and 
hydroxygalangal (not in the register), together with 4 different short-chain carboxylic acids acetic acid, 
propionic acid, isobutanoic acid and butanoic acid and propionic acid. The alcoholic fragments of these 
esters do not bear special structural features as compared to the other candidate phenols in this FGE. The 
carboxylic acid fragments have been evaluated previously to be of no safety concern (EFSA, 2008ag). 
Alkyl-substituted phenols 
[FL-no: 04.020, 04.021, 04.065, 04.066, 04.070, 04.072, 04.073, 04.078 and 04.095; alcohol moieties of FL-
no: 09.253, 09.893 and 09.337]. 
In rabbits, given a single oral 200 mg/kg bw dose of 2- and 3-methylphenols, these phenols were 
hydroxylated to 2,5-dihydroxytoluene to a minor extent (< 3 % of the dose), while up to 10 % of p-cresol 
was oxidised and excreted as p-hydroxybenzoic acid. With both 3- and 4-methylphenol, also trace amounts 
of 3,4-dihydroxytoluene were found. The non-acidic phenolic metabolites (i.e. the parent cresols and the 
dihydroxytoluenes) were excreted mainly as the glucuronic acid (60-72 % of the dose) and sulphate 
conjugates (10-15 % of the dose) within 24 hours. p-Hydroxybenzoic acid was excreted as an unidentified 
conjugate and as free acid (Bray et al., 1950a). 
One gram doses (~ 300 – 500 mg/kg bw) of 2,3-, 2,4- 2,5-, 2,6-, 3,4- or 3,5- dimethylphenol given to rabbits 
were excreted as xylenyl sulphates (8 – 16 %) and ether glucuronides (50 – 72 %). Small amounts (1-2 %) of 
ester glucuronides were also observed. Only 1 – 3 % of the administered dose was excreted unconjugated. 
Small amounts of ring and side-chain hydroxylation products were also formed, and for the 2,6- and 3,5-
xylenols these could be identified as 2,5-dihydroxy-1,3-dimethylbenzene (= 1,3-dimethyldihydroquinone). 
Total urinary recoveries ranged from 84 – 96 % of the dose (Bray et al., 1950b). Based on another study by 
the same research group (Bray et al., 1950a), it is likely that these amounts were excreted within 24 hours 
after dosing. 
According to data presented in an extensive review on biotransformations, monoalkyl-substituted phenols are 
mainly conjugated with sulphate or glucuronic acid (Williams, 1959a). To a small extent, they undergo side-
chain oxidation and ring hydroxylation to form a second hydroxyl group, in ortho or para position to the 
existing hydroxyl group. Thymol (5-methyl-2-isopropylphenol) and carvacrol (2-methyl-5-isopropylphenol) 
are also excreted via conjugation with sulphates and glucuronic acid. Thymoquinol (2-isopropyl- 5-methyl-
1,4-benzenediol) has been detected as a minor oxidation product of thymol. At least for thymol a higher 
urinary excretion of free parent compound than with phenol may occur, as has been observed in the dog 
(Williams, 1959a). 
In rats, less than 0.2 % of a 100 mg/kg bw oral dose of p-cresol was ring hydroxylated and o-methylated to 
yield 4- and 5-methylguaiacol [2-methoxy-4- and 5-methylphenol; ratio 2 to 1] (Bakke, 1970). 
In rat liver slice incubations with 2-, 3- or 4-methylphenol, the latter isomer appeared to be ~ 10 times more 
cytotoxic than the o- and m- forms. Especially for the p-isomer (i.e. 4-methylphenol), cytotoxicity was 
mediated by bioactivation and could be influenced by modification of the intracellular GSH levels. 4-
Methylphenol caused profound depletion of GSH, which preceded onset of cytotoxicity. Reactive 
intermediates in 4-methylphenol metabolism were also capable of covalent binding to protein. No 
cytotoxicity was observed with p-hydroxybenzyl alcohol, a primary metabolite of 4-methylphenol 
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(Thompson et al., 1994). The authors speculated that a reactive intermediate leading to p-hydroxybenzyl 
alcohol could be the cause of the cytotoxicity of 4-methylphenol. In subsequent studies it was demonstrated 
with 4-methylphenol, 4-ethylphenol and p-isopropylphenol that the reactive intermediate is a quinone 
methide, which can be detoxified by conjugation with GSH. The most cytotoxic congener of this series 
appeared to be the p-isopropylphenol. 4-Methylphenol appeared to be the least cytotoxic of these three para-
substitued phenols (Thompson et al., 1995a). 
Despite the fact that 2- and 3-methylphenols are considerably less cytotoxic than the p-isomer, also with 2- 
and 3-methylphenol some decrease of hepato-cellular GSH has been observed, which could indicate the 
involvement of an epoxide in the metabolism towards 2,5-dihydroxytoluene (Bray et al., 1950a; Thompson 
et al., 1994). Further, from the data by Thompson et al., (1994), the involvement of a quinone-hydroquinone 
redox cycle in hepatocellular GSH depletion by 2- and 3-methylphenol cannot be excluded.  
The kinetic behaviour of 4-methylphenol was investigated in male OFA rats (mean body weight = 310 g) 
that received an intravenous bolus of 2 ml isotonic saline or 3 mg 4-methylphenol in 2 ml isotonic saline. 
Blood samples were collected at 0, 5, 30, 60, 120, 180 and 240 minutes after administration of 4-
methylphenol and urine was collected at one hour intervals. The serum concentration of 4-methylphenol at 
the 5-minute time point was 6.7 ± 1.4 mg/l and decreased gradually to 0.6 ± 0.3 mg/l at 240 minutes post-
administration. No 4-methylphenol was found in the serum of control rats. Urinary excretion of 4-
methylphenol was 23 ± 10 % of the administered dose over the 4 hours observation period, and the half-life 
was 1.5 ± 0.8 hours. Total clearance (CLt) was 23.2 ± 4.5 ml/hr/kg, but renal clearance (CLr) was 
substantially lower at 4.8 ± 2.0 ml/hr/kg. The volume of distribution (Vd) was determined to be 2.9 ± 1.4 
l/kg. No attention was paid to the possible renal excretion of conjugation products. A putative urinary 
metabolite of 4-methylphenol was not identified (Lesaffer et al., 2001). 
The systemic availability and the pharmacokinetics of thymol were determined in 12 fasted healthy human 
male volunteers that each received a single 1.08 mg oral dose of thymol. Venous blood samples and urine 
were collected at various time intervals up to 72 hours post administration of the test substance. Thymol was 
absorbed rapidly as evidenced by the detection of thymol sulphate in plasma 20 minutes after dose 
administration. Mean peak plasma concentration of thymol sulphate, achieved at 1.97 ± 0.77 hours, was 93.1 
± 24.5 ng/ml. The mean terminal elimination half-life for thymol was calculated to be 10.2 ± 1.4 hours. The 
same metabolite profile was seen for all the subjects. Free thymol or thymol glucuronic acid were 
undetectable in human plasma. In contrast, in urine the metabolites thymol sulphate and thymol glucuronic 
acid were found. The combined amount of thymol sulphate and thymol glucuronide excreted in 24-hour 
urine was 16.2 ± 4.5 % of the administered dose of thymol, with a sulphate / glucuronide ratio of ~ 1.15 /1, 
as determined in one of the volunteers. No further renal elimination could be observed at later time points. 
The authors argued that the urinary glucuronic acid could have been formed in the kidney subsequent to 
renal hydrolysis of the sulphate conjugate present in the blood (Kohlert et al., 2002). 
Alkoxy-substituted phenols 
[FL-no: 04.076, 04.077, 04.091 and 04.092] 
Female rabbits (2.5 to 3.5 kg) were administered a suspension of 0.7 g 1-methoxy-4-methylbenzene or 0.7 g 
4-methoxyanisole once via oral gavage. The mean quantity of the administered dose excreted in the urine 
within 24 hours following administration was 85 and 94 % of the dose, respectively. With 4-methylanisole 
27 % of the dose was converted into phenols, mainly 4-methylphenol (i.e. a O-demethylation product) or 
some 4-hydroxybenzoic acid, which were excreted as their sulphate and glucuronic acid conjugates. The 
major part of the dose (on average 58 %) was excreted as glucuronide and glycine conjugates of 4-
methoxybenzoic acid (i.e. oxidised at the methyl group). With 4-methoxyanisole only glucuronic acid and 
sulphate conjugates of phenolic metabolites (mainly 4-methoxyphenol and small amounts of quinol) were 
seen together with some unconjugated phenols. In a similar study, also 0.7 g of anisic acid (4-methoxy 
benzoic acid was given to rabbits. No O-demethylation was observed, but within 24 hours on average 57 % 
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and 38 % of the dose were recovered as the glucuronide ester and glycine conjugate of the parent compound, 
respectively (Bray et al., 1955). 
In cats, a single 20 or 40 mg/kg bw intravenous dose of 14C-2,6-dimethoxyphenol was excreted mainly as 
conjugated (90-93 % as 2,6-dimethoxy-4-hydroxyphenol disulphate) and unconjugated (3 % as 2,6-
dimethoxy-4-hydroxyphenol) within 24 hours of dosing. Free (5 %) and conjugated (2 % with glucuronic 
acid) forms of the parent phenol (all expressed as percentage of urinary radioactivity) were also detected. 
Total urinary excretion over the first 24 hours post dosing amounted to 75 - 91 % of the dose in males and 
85-80 % of the dose in females (for 20 and 40 mg/kg bw, respectively). Biliary excretion was only observed 
during the first 6 hours post dosing and amounted to ~ 3 - 7 % of the dose (metabolites not further identified) 
(Miller et al., 1976). 
In humans, 73 % of a 50 mg dose of guaiacol (i.e. 2-methoxyphenol) was excreted probably as conjugates 
(not further identified) within 14 hours  (Sedivec & Flek, 1970) (paper in Czech language with abstract in 
English). 
Phenols with alkoxy-, alkenyl- or ketonic ring substituents 
[FL-no: 04.061 (vinyl) and FL-no: 07.142; 07.154; 07.164; 07.243 and 07.234 (ketonic)] 
Like the p-alkylphenols, such as 4-methylphenol, 4-ethylphenol and, 4-isopropyl-phenol (see above), 2-
methoxy-4-alkylphenols can form electrophilic quinone methide intermediates at high cellular 
concentrations. An in vitro study revealed that 2-methoxy-4-methylphenol, 2-methoxy-4-ethylphenol, 2-
methoxy-4-propylphenol, 2-methoxy-4-isopropylphenol, 2-methoxy-4-allylphenol (= eugenol) and 4-allyl-
2,6-dimethoxyphenol are oxidised to quinone methide intermediates in rat liver slices. The half-lives of 
quinone methide intermediates formed from these substances were 1, 6, 6, 87, 408 and 4332 seconds, 
respectively. The data suggest that quinone methide intermediates with half-lives in the 10 seconds to 10 
minutes range have optimal reactivity and stability for causing cytotoxicity. Outside this range, the quinone 
methide either reacts with the solvent water rather than the target biomacromolecules, or has only low 
reactivity towards cellular nucleophiles. In both cases this is reflected in lower cytotoxicity of the respective 
parent phenol (Thompson et al., 1995b). If concentrations of the quinone methide intermediates are 
insufficient to deplete intracellular GSH, they may be detoxicated via conjugation with this scavenger 
(Thompson et al., 1994; Thompson et al., 1995a; Thompson et al., 1995b). 
Vinyl- and alkoxy- substituted phenol 
[FL-no: 04.061] 
No data have been submitted to describe or support the metabolism of 2,6-dimethoxy-4-vinylphenol [FL-no: 
04.061] with respect to the vinyl ring substituent. However, 4-vinylphenol is a known metabolite of styrene 
(vinyl benzene) and data from the metabolism of the latter substance may be useful to support the 
metabolism of [FL-no: 04.061].  
When animals or humans are exposed to styrene, 4-vinylphenol can be identified in the urine as glucuronic 
acid or sulphate conjugates (Bakke & Scheline, 1970; Pfäffli et al., 1981; Manini et al., 2003). In addition, 
after intraperitoneal injection of styrene in rats, p-hydroxymandelic acid, p-hydroxy-benzoic acid and p-
hydroxyhippuric acid, which may be secondary metabolites of 4-vinylphenol after oxidation of the vinyl 
double bond, have been identified (Pantarotto et al., 1978). 4-Vinylphenol was shown to be an intermediate 
in the subsequent and rapid formation of 1-(4-hydroxyphenyl)ethane-1,2-diol as a metabolite of styrene 
(Watabe et al., 1984). The putative intermediate 4-hydroxystyrene-7,8-epoxide was extremely unstable in 
aqueous environment but could be trapped in the presence of mercaptoethanol. 4-Vinylphenol is a known 
liver and lung toxicant. To elicit a toxic response in these tissues, bioactivation of 4-vinylphenol is required 
via cytochromes P450 (CYP 2E1 and 2F2). Microsomal preparations of mouse liver and lung appeared to be 
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far more active than microsomes from the same tissues in the rat. In addition, metabolism of 4-vinylphenol in 
mouse lung microsomes was also observed to occur with glutathione, also in absence of an active 
cytochrome P450 system (Carlson et al., 2001; Carlson et al., 2002). However, 4-vinylphenol is not a potent 
GSH-depleting agent in liver and lung tissue in vivo (Turner et al., 2005). It is noted that no specific 
metabolism studies with 4-vinylphenol in which metabolites have been identified, have been done up to now, 
apart from one study in a bacterial system. In this study it has been shown that Nocardia is capable of 
producing 1-(4-hydroxyphenyl)ethanol and 4-hydroxyacetophenone when incubated with 4-vinylphenol. 
The authors hypothesised that in this conversion a quinone methide intermediate might be involved (Lee & 
Rosazza, 2002). 
Alkoxy and ketone-substituted phenols 
[FL-no: 07.142, 07.154, 07.164, 07.243 and 07.234] 
No data have been submitted for any of these five candidate flavouring substances. However, for some 
structural analogues, data were submitted or could be retrieved from the public domain literature. 
Acetophenone [FL-no: 07.004] is an intermediate in the metabolism of ethylbenzene. It was made 
conceivable by studying various intermediates that acetophenone may undergo side-chain omega oxidation 
and keto-reduction, leading via phenyl glycol aldehyde to mandelic acid. When methyl-14C-acetophenone 
was given to rats, 10 % of the radioactivity was exhaled as carbon dioxide within 4 hours and 30 % within 13 
hours post dosing, which demonstrated length reduction of the side chain. Benzoic acid is a known 
metabolite of ethylbenzene (Sullivan et al., 1976). From the pathway indicated above it may be concluded 
that the carbon dioxide is released by decarboxylation of mandelic acid, which results in the formation of 
benzoic acid. 
In rabbit liver S9 fraction, incubated with phenylacetone (1-phenyl-2-propanone) the following metabolites 
could be detected: 1-phenyl-2-propanol from ketoreduction (~ 90 % of all material retrieved), 1-phenyl-1,2-
propanediol, 1-phenyl-1-hydroxypropanone and benzoic acid. Within 60 minutes almost all parent 
compound had been converted. Reduction of the keto-group was also observed with 1-phenyl-butan-2-one 
and with 1-phenyl-3-methyl-butan-2-one (Kammerer et al., 1978).  
Vanillyl acetone [FL-no: 07.005] (i.e. 4-(4-hydroxy-3-methoxyphenyl)butan-2-one)) administered to rats in 
single oral or intraperitoneal doses (100 mg/kg bw) was excreted in the urine mainly as glucuronic acid 
and/or sulphate conjugates, quantitatively in an essentially similar way, after both routes. Vanillyl acetone 
(conjugates) comprised 54 % of the dose and total urinary excretion amounted to 96 %10 of the dose within 
24 hours post dosing, and was complete within 48 hours. In some separately treated animals (with 400 mg/kg 
bw) biliary excretion of vanillyl acetone (25-46 % of the dose) was observed together with zingerol (3-7 %) 
and trace amounts of other metabolites, indicating a significant enterohepatic cycle. The only metabolite 
which was excreted in appreciable amounts in unconjugated form was homovanillic acid (= (4-hydroxy-3-
methoxyphenyl)acetic acid, which was excreted in total amounts of ~ 7 % of the dose. Reduction of the 
ketone to zingerol (12 %) was also observed along with lesser amounts of ring O-demethylation to 4-(3,4- 
dihydroxyphenyl)butan-2-one (6 %). Other metabolites included homovanillyl alcohol, 4-hydroxy- and 1-
hydroxy-(4-hydroxy-3-methoxyphenyl)butan-2-one, 4-(4-hydroxy-3-methoxyphenyl)butane-1,2- and -2,3-
diol, dihydro-ferulic acid (= 3-(4-hydroxy-3-methoxyphenyl)-2-propanoic acid), homo-proto-catechuyl 
alcohol (2-(3,4-dihydroxyphenyl)ethanol), and 4-(3,4-di-hydroxyphenyl)butan-2-one and -butan-2-ol. In bile 
duct ligated animals, no O-demethylation products could be detected in the urine and in separate in vitro 
studies it was demonstrated that gut microflora can O-demethylate vanillyl acetone. These findings indicate 
that the urinary O-demethylation products probably result from conversions carried out by the intestinal flora 
(Monge et al., 1976). 
                                                     
 
10 Percentages of excretion are the averages for both routes. 
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When rats were dosed intravenously with 4-phenyl-2-butanone, in the blood small amounts of the reduction 
product 4-phenyl-2-butanol could be detected. The analytical methods were not designed to include 
conjugated products (Kitamura et al., 1999).  
With several zingerone analogues 5-hydroxylation (producing a catechol) of the vanillyl ring (= 4 hydroxy -
3-methoxyphenyl) has been observed in phenobarbital-pretreated rat liver microsomes. The efficiency of 5-
hydroxylation depended on the length of the alkenyl-ketonic side chain and the position of the double bond 
in this chain (Lee & Kumar, 1982). The paper was not sufficiently detailed to evaluate the rate of this 
conversion. In addition, the fact that only microsomes from phenobarbital-pretreated rats were used may 
reduce the applicability of this finding for human risk assessments. 
Polyphenols (catechol, resorcinol or quinol) 
Polyphenols are not represented in this FGE as candidate flavouring substances. However, in general ring 
hydroxylation of phenols may result in the formation of polyphenolic metabolites. For that reason some 
attention is given below to the metabolism of polyphenols. 
Rabbits were fed single 100 mg/kg bw doses of benzene-1,3-diol [FL-no: 04.047] or 100 – 200 mg/kg bw 
doses of quinol via stomach tube. Urinary analysis revealed that within 24 h after administration, 52 % of the 
dose was excreted as glucuronic acid conjugates, 13.5 % as sulphate conjugates, and 11.4 % as free benzene-
1,3-diol. Quinol was excreted for 43 % as glucuronide and for 30 % as sulphate. Only trace amounts of 
parent quinol could be found. In this paper results from the same research group have been quoted, which 
show that catechol is excreted in rabbit urine for 2 % as parent substance, 70 % as glucuronide and for 18 % 
as sulphate conjugate. With catechol, but not with quinol or benzene-1,3-diol a trace amount of the sulphate 
conjugate of the oxidation product hydroxyquinol (= 1,2,4-trihydroxybenzene) was found (Garton & 
Williams, 1949). 
Single 112 or 225 mg/kg bw doses of 14C-benzene-1,3-diol were administered orally to male and female 
F344 rats. Within 24 hours ca. 94 % of the low dose was excreted, mainly via the urine. The high dose was 
eliminated slightly slower (~ 80 % in 24 hours urine). Virtually no radioactivity was exhaled. Approximately 
70 % of the dose was excreted as glucuronic acid conjugates in the urine of both sexes. A greater portion of 
sulphate conjugates was detected in the urine of females. Males excreted a larger percentage of a diconjugate 
containing both sulphate and glucuronic acid conjugates. About 2 % of the dose was excreted in the faeces of 
both sexes. In addition, daily oral doses of 225 mg benzene-1,3-diol/kg bw were administered for five 
consecutive days. This regimen did not significantly alter the ratio of metabolic products observed in the 
single dose experiment (Kim & Matthews, 1987). 
Candidate Substances 
3,4-Methylenedioxyphenol [FL-no: 04.080] 
No studies have been submitted to support the evaluation of this substance. As the methylenydioxy-ring may 
be looked at as a (cyclic) acetal, it might be expected that this ring may be opened and demethylated, which 
would result in the formation of 1,2,4-trihydroxybenzene (and formaldehyde). The same loss of the 
methylenedioxy-ring has been reported for safrole, myristicin (Figure III.1) and some related compounds, for 
which the loss of the methylenedioxy-group may be as much as 61-92 % of the dose after oral 
administration, based on urinary metabolites or exhalation of methylenedioxy-derived carbondioxide 
(Klungsoeyr & Scheline,1982; Kamienski & Casida, 1970).  
Also with piperonyl butoxide (=[3,4-(methylenedioxy)-6-propylbenzyl]butyl diethyleneglycol ether (Figure 
III.1), considerable loss of the dimethylendioxy-ring was found ( ~ 70 % of the dose), but no loss of the 
entire propyl or butyl diethyleneglycol side chains. In contrast to e.g. safrole or piperonyl butoxide, when 
rats were given piperonyl alcohol, piperonal or piperonylic acid (3,4-methylenedioxylbenzyl alcohol, -
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benzaldehyde or -benzoic acid, respectively (Figure III.1)) no loss of the dimethylenedioxy-ring was 
observed. With tropital (= piperonal bis(2-(2-butoxyethoxy)ethyl) acetal; Figure III.1) extensive loss of both 
alcohol side chains was observed (resulting in the formation of piperonyl aldehyde and further metabolic 
products, including glycine and glucuronic acid conjugates of piperonylic acid), but hardly any loss of the 
methylenedioxy-ring. From these observations it may be concluded that loss of the methylenedioxy-ring is a 
major route of metabolism when more rapid elimination is not possible, e.g. because no rapid options for 
conjugation are present. On the basis of this conclusion, it may be expected that the candidate flavouring 
substance 3,4-methylenedioxyphenol [FL-no: 04.080] is not metabolised via loss of the methylenedioxy-ring 
but that it may rather be conjugated with sulphate or glucuronic acid, similar to the other phenols. In 
addition, some ring hydroxylation at the ortho-position cannot be excluded but this may also be expected to 
represent a minor route of metabolism. 
 
Figure III.1: Chemical structures of methylendioxybenzene derivatives 
 
4-Isopropylphenol [FL-no: 04.073] 
Hepatocellular toxicity was suggested as time-dependent intracellular potassium leakage from precision-cut 
rat liver slices incubated with 2 mM 4-isopropylphenol for six hours. A significant depletion of intracellular 
glutathione levels in rat liver slices after one hour of incubation suggested the formation of intermediates that 
react with glutathione. Supplementation of the incubates with N-acetyl cysteine or metyrapone reduced 
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cytotoxicity. An in vitro study using rat liver microsomes in the presence of NADPH and 3H-glutathione 
provided evidence that 4-isopropylphenol may be oxidised to reactive quinone methide intermediates and 
then conjugated with glutathione (Thompson et al., 1995a).  
2,4-Dimethylphenol [FL-no: 04.066] 
2,4-Dimethylphenol (2,4-DMP) was administered to male Sprague-Dawley rats by intravenous bolus 
injection at 30 mg/kg bw or intraperitoneal bolus injection at 30 mg/kg bw and concentrations of 2,4-DMP 
and its conjugated metabolites in plasma were measured. Only minute amounts of unchanged parent 
compound were detected one hour after intravenous bolus injection of 2,4-dimethylphenol, indicating rapid 
and extensive metabolism. Thirty minutes after the intravenous bolus injection of 2,4-dimethylphenol, the 
concentration of unchanged compound in plasma was 0.12 ± 0.02 µg/ml, and the concentration of total 
conjugates was 8.55 ± 0.61 µg/ml. Thirty minutes after the intraperitoneal bolus injection, the concentration 
of unchanged compound in plasma was 1.16 ± 0.30 µg/ml, and the concentration of total conjugates was 
19.45 ± 3.80 µg/ml. The relative amounts of 2,4-dimethylphenol and metabolites in plasma amounted to ~ 
5.6, 53 and 41 % for parent compound, glucuronic acid conjugate and other conjugates (probably sulphate), 
respectively (Kaka et al., 1982). 
2,4-Dimethylphenol [FL-no: 04.066] and 2,4,6-Trimethylphenol [FL-no: 04.095] 
In vitro metabolism studies provide evidence of a bioactivation pathway for some o-substituted p-
alkylphenols, but not for others. For 2,4-dimethylphenol and 2,4,6-trimethylphenol potential for cytotoxicity 
arises from the oxidative formation of reactive quinone methide (QM) intermediates. QM formation was 
estimated to be 0.28 ± 0.07 and 0.17 ± 0.02 nmol per nmol of P450 per min using rat liver microsomes and 
16 ± 3 and 17 ± 2 pmol per 106 cells per min using rat hepatocytes, respectively. These QM formation levels 
were considerably lower than the rates for other investigated phenols containing tert-butyl groups, which 
were in the range of 0.40 – 0.70 nmol per nmol of P450 per min using rat liver microsomes and 38 – 62 pmol 
per 106 cells per min using rat hepatocytes. At an incubation concentration of 0.30 mM of the parent phenol, 
QM reactive intermediates are effectively detoxicated by the available glutathione for 2,4-dimethylphenol, 
2,4,6-trimethylphenol and 2,6-di-tert-butyl-4-methylphenol since they were not cytotoxic when incubated 
with rat hepatocytes for two hours. However, under the same experimental conditions, 2-tert-butyl-4-
methylphenol, 2-tert-butyl-4,6-dimethylphenol, and 6-tert-butyl-2-(hydroxy-tert-butyl)-4-methylphenol 
destroyed 100 % of rat hepatocytes after complete glutathione depletion (Bolton et al., 1992). The results of 
this study demonstrate that the nature of the o-substituents to the ring affects the stability of charge 
separation within the various quinone methide metabolites and thereby their reactivity and toxicity. 
3-Methoxyphenol [FL-no: 04.076] 
Cytotoxicity studies in isolated rat hepatocytes were used to elucidate the cytochrome P450- catalysed 
bioactivation pathway of 3-methoxyphenol to form reactive metabolites. No in vivo data on metabolism were 
presented, but it was shown that intraperitoneal administration of 300 or 400 mg 3-methoxyphenol/kg bw to 
mice resulted in profound hepatotoxicity, and even death. Using "intervention agents" such as cytochrome 
P450 inhibitors, radical scavengers and DT-diaphorase inhibitors, it was demonstrated that 3-methoxyphenol 
could be metabolised to a reactive intermediate that could generate reactive oxygen species and might be 
able to result in alkylation of protein SH groups. As in microsomal incubations with 3-methoxyphenol no 
formaldehyde production was observed11, it was concluded that no O-demethylation took place. In addition, 
it was demonstrated that upon metabolic activation, 3-methoxyphenol is a more potent depletor of 
intracellular GSH than 4-methoxyphenol and 2-methoxyphenol. In microsomal preparations with 3-
methoxyphenol, fortified with GSH, no indications of ring epoxidation were obtained, because no 3-
methoxyphenol-SG or resorcinol-SG conjugates were found. Instead, formation of a GSH-conjugate of 4-
                                                     
 
11 Moridani, 2005; Written correspondence between FLAVIS working group and study authors, 2005. 
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methoxycathecol was observed. In separate studies it could be demonstrated that 4-methoxycatechol may 
trigger toxicity to hepatocytes via redox reactions involving 4-methoxy-ortho-quinone (Moridani et al., 
2003). 
4-Methoxyphenol [FL-no: 04.077] 
Studies in isolated rat hepatocytes and liver microsomal incubates were used to elucidate the cytochrome 
P450- catalysed bioactivation pathway of 4-methoxyphenol (= 4-hydroxyanisole) to form reactive 
metabolites and trigger cytotoxicity. Cytotoxicity of 4-methoxyphenol could be influenced by co-incubation 
of hepatocytes and 4-methoxyphenol with inhibitors of CYP2E1 or DT-diaphorase or with GSH or depletors 
thereof. o-Quinone traps or scavengers of reactive oxygen species were not very effective. When the 
substance was incubated in microsomal preparations, no formaldehyde was released, indicating absence of 
O-demethylation. However, hydroquinone and p-quinone could be detected, and in addition also the GSH 
conjugate of hydroquinone was found if GSH was included in the incubates. The authors propose that ring 
epoxidation and/or P450-mediated one electron oxidation as bioactivation routes to convert 4-
methoxyphenol to the reactive intermediate species, 4-hydroxyanisole epoxide and p-quinone, occurs rather 
than O-demethylation / ring hydroxylation / ipso attack mechanism. The cytotoxicity of 4-methoxyphenol 
results from covalent binding of hydroquinone / p-quinone to proteins rather than from oxidative stress 
(Moridani et al., 2002). 
The human metabolism of 4-hydroxyanisole (= 4-methoxyphenol) was investigated using urine samples 
from three melanoma patients being treated therapeutically with this substance and five untreated healthy 
volunteers (Pavel et al., 1989). The substance was administered to patients by intra-arterial infusion at a 
concentration of 20 mg/ml isotonic saline at a dose rate of 40 g/24 hours for four days. In the urine samples 
of the patients, 4-hydroxyanisole, 3,4-dihydroxyanisole 3-hydroxy-4-methoxyanisole, 4-hydroxy-3-
methoxyanisole and hydroquinone were detected. However, none of these compounds were detected in the 
urine of healthy volunteers except for minute quantities of hydroquinone. All metabolites in the urine of the 
patients were excreted both as sulphates and glucuronides with a small percentage found in the unconjugated 
form. Of the urinary metabolites, 3,4-dihydroxyanisole made up 85 – 90 % of the total, and 3-hydroxy-4-
methoxyanisole and 4-hydroxy-3-methoxyanisole made up 10 – 15 % of the total. The presence of 
“considerable amounts” of hydroquinone in the urine samples of patients (in contrast to very low quantities 
of hydroquinone detected in the urine of healthy volunteers) was attributed to O-demethylation of 4-
hydroxyanisole as a possible metabolic route based on previous research, although it was mentioned above 
that O-demethylation is not a major metabolic pathway for 4-methoxyphenol. The authors concluded that: 
“…the metabolism of 4-methoxyphenol proceeds preferentially via ring hydroxylation and is in accordance 
with the generally recognised phase I step of drug metabolism. The o-hydroxyphenolic compounds formed 
are, however, potentially toxic, and the ring hydroxylation is usually coupled to the phase II reaction, such 
as glucuronidation or sulphation…thus forming metabolites that are more readily eliminated than the parent 
compound” (Pavel et al., 1989). Because of the high amounts of catechol derivatives in human urine, as 
observed by Pavel et al., it has been speculated that the human metabolism may differ from that of rats 
because no catecholic metabolites of 4-methoxyphenol could be detected in rat liver microsomal incubates 
(see above) (Moridani et al., 2002). 
Female rabbits (2.5 to 3.5 kg) were administered a suspension of 0.7 g 4-methoxyphenol once via oral 
gavage. The mean quantity of the administered dose excreted via the urine within 24 hours following 
administration was 13 % (10 – 15 %) for the ethereal sulphate, 69 % (65 – 73 %) for the ether glucuronide, 
and 1 % (0 – 2 %) for the free 4-methoxyphenol. 4-Methoxyphenol was also determined to be partially 
demethylated resulting in ~ 3 % of the dose being excreted as quinol (Bray et al., 1955). 
Acetovanillone [FL-no: 07.142] 
Male Wistar rats (200 – 350 g) were administered a 1 mmol (166 mg) acetovanillone/kg bw dose via 
stomach tube as a solution in propylene glycol. Control animals received only propylene glycol. Urine 
Flavouring Group Evaluation 22, Revision 1
 
 
49 EFSA Journal 2011; 9(5):1990 
samples were collected at 24-hours intervals for five days. Acetovanillone was excreted rapidly in the urine 
(80 % of the dose within the first 24 hours), mainly as the parent compound but also as the demethylated 
compound (3,4-dihydroxyacetophenone; 6 %) and three ring-hydroxylated metabolites (together 11.3 %) 
(see Figure III.2). Additionally, minor metabolic pathways produced the p-methoxy derivative 
(acetoisovanillone), a dimethoxyhydroxy derivative, and two 1-phenylethanol derivatives (1-(4-hydroxy-3- 
methoxyphenyl)ethanol and 1-(3,4-dihydroxyphenyl)ethanol) formed by ketone reduction of acetovanillone 
and 3,4-dihydroxyacetophenone, respectively. The positions of the substituents of the three ring-
hydroxylated metabolites and the dimethoxy-hydroxy metabolite, were not fully ascertained in the study, but 
based on mass spectrometry and comparison with fragmentation patterns of know metabolites, they were 
tentatively deduced to be 2,4-dihydroxy-3-methoxyacetophenone, 4,5-dihydroxy-3-methoxyacetophenone, 
4,6-dihydroxy-3-methoxyacetophenone and 3,4-dimethoxy-5-hydroxy-cetophenone, respectively. Hardly 
any metabolites were found in the faeces. The total urinary excretion of all metabolites over the entire 
observation period was 96 ± 4 % of the dose. The metabolites excreted in the urine were mainly glucuronic 
acid and/or sulphate conjugates. From unpublished data it was concluded that the amounts of free 
metabolites were 15-40 % of total amounts of metabolites excreted (Gjertsen et al., 1988). 
5-Paradol [FL no: 07.234] 
When studying the metabolism of shogaol (= 1-(4-hydroxy-3-methoxyphenyl)-deca-4-ene-3-one) (Surh & 
Lee, 1992), it was found that the keto-reduction of 5-paradol (= 1-(4-hydroxy-3-methoxyphenyl)-3-decanone 
[FL no: 07.234]), which is an intermediate in shogaol metabolism, is mediated by liver cytosolic reductases. 
When 5-paradol was given to bile duct-cannulated rats via intraperitoneal injection, neither parent substance 
nor metabolites were excreted via the urine. In bile, free and conjugated 5-paradol and the keto-reduced 
metabolite (1-(4-hydroxy-3-methoxyphenyl)-decan-3-ol) could be detected. No further details about dose, 
recovery or nature of the conjugates (whether phenolic or alcoholic; sulphate or glucuronide) were available. 
Based on observations with vanillyl acetone (see above) ring hydroxylation may also have occured with 5-
paradol, but such metabolites were not reported and it is not clear whether such metabolites have been 
looked for (Watabe et al., 1981; only abstract available). 
Nibovan [FL-no: 08.134] 
Nibovan [FL-no: 08.134] (4-hydroxy-3-methoxymandelic acid or vanillylmandelic acid) has been identified 
as an endogenous break-down of adrenalin and nor-adrenalin in humans. The substance can be determined in 
plasma and is eliminated via the kidneys. A plasma half-life of approximately 0.5 hours has been mentioned. 
In contrast to other phenolic metabolites of adrenalin and nor-adrenalin, vanillylmandelic acid is not 
conjugated to sulphate, but no systematic study on metabolism of [FL-no: 08.134] has been submitted 
(Eisenhofer et al., 1996; Eisenhofer et al., 2004; Fukuda et al., 1996; Yang et al., 1996). For the related 
substance L(+) mandelic acid (2-phenyl-2-hydroxyacetic acid), which in humans is virtually completely 
eliminated via the urine, metabolic options are conversion into oxo(phenyl) acetic acid (ca. 20 % of the 
administered dose) and benzoic acid (ca. 2 % of the administered dose). The D(-) stereoisomer is 
metabolised to a less extent (Nagwekar & Kostenbauder, 1970). Benzoic acid may be further metabolised 
with glycine to yield hippuric acid. Whether other conjugates of mandelic acid can be formed is not clear 
from the submitted data. Direct conjugation of the carboxylic acid moiety with amino acids has been 
described for phenylacetic acid (EFSA, 2009f). 
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Figure III.2. Metabolic pathways for acetovanillone in the rat (Gjertsen et al., 1988). 
III.4. Summary and Conclusions 
It can be assumed that the phenolic substances within this group are well absorbed. The phenol esters in the 
group will be hydrolysed, probably already in the intestinal lumen by pancreatic enzymes. 
After absorption, the substances in this group are easily metabolised and excreted. The most important 
metabolic conversions are straightforward conjugation of the phenolic group with sulphate or glucuronic 
acid at the hydroxy group, followed by rapid excretion usually via urine. For 5-paradol, considerable 
excretion via the bile has been observed. 
Conjugation with sulphate or glucuronic acid has been observed in many species, but in cats and pigs, in 
contrast to other species including humans, enzymes catalysing sulphation and glucuronidation of phenols, 
respectively, are not very active, if not absent. As a result of the limited capacity of these two species to 
conjugate phenols, toxicity data obtained with cats or pigs may be considered of limited relevance for 
humans. With rabbits and rats, it has been observed that sulphation may have limited capacity at high dose 
levels. At those high dose levels, glucuronidation increases in importance. This may be due to depletion of 
body sulphate stores, but also differences in substrate affinity and/ or maximum conjugation velocities of the 
various enzymes have been shown to play a role in the observed shift in conjugation ratio when dose levels 
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are increased. The available data indicate that the efficiency of the conjugation reactions is not very much 
influenced by the presence of ring substituents, provided that these are not too bulky. 
Ring hydroxylation, side chain oxidation and O-demethylation occur to a much smaller extent than 
conjugation. This may be related to the high velocity with which these phenolic substances are conjugated in 
the first place. Products of the oxidative metabolic pathways may include quinones and catechols, which may 
trigger a cytotoxic response if their concentration or formation rate overwhelms their detoxication via 
glutathione conjugation. Reduced quinones (i.e. hydroquinones) and catechols are also substrates for 
sulphate and glucuronic acid conjugation. 
In vitro metabolism studies with rat liver slices have provided evidence of a bioactivation pathway for para-
substituted alkylphenols at high concentrations. With some p-isomers of alkyl-substituted phenols, as well as 
some o-methoxy-4-alkylphenols, cytotoxicity arises from the oxidative formation of reactive quinone 
methide intermediates. At sufficiently low concentrations this reactive intermediate is inactivated by 
conjugation with glutathione. At higher concentrations, the quantity of quinone methide intermediates 
exceeds glutathione availability which resulted in cytotoxicity. Based on an observation in a bacterial 
incubation system with 4-vinylphenol, formation of a quinone methide intermediate can also not be excluded 
from 2,6-dimethoxy-4-vinylphenol [FL-no: 04.061], but because of the presence of the two methoxy groups, 
this intermediate substance is probably not reactive enough to cause cytotoxicity. 
Some of the candidate substances possess a ketone function in the side chain, which provides an additional 
metabolic option for metabolism. In principle, such phenol derivatives may also be excreted in the urine as 
conjugates of glucuronic acid and sulphate. In addition to this, minor metabolites may be formed through 
ring hydroxylation, or side chain omega-oxidation, which may result in chain length reduction. Reduction of 
the ketone to the corresponding phenyl alcohol has also been reported. With 5-paradol conjugation and keto-
reduction, but no chain length reduction or oxidations on the aromatic ring, have been reported. The 
candidate substance nibovan [FL-no: 08.134] is an endogenous metabolite of adrenalin and nor-adrenalin. 
This substance is rapidly eliminated from the blood and excreted via the kidneys. Data on conjugations are 
not available. 
Overall, for the candidate substances in this group the phenolic groups are conjugated with glucuronic acid 
or sulphate very efficiently and these conjugation pathways are not easily saturated. Although especially at 
high dose levels reactive metabolites such as quinones, catechols or quinone methides may be formed, it is 
not expected that the formation of these metabolites would overwhelm the capacity of conjugation with 
glutathione at the estimated levels of intake as flavouring substance. Even for an exceptionally susceptible 
species such as the cat, acute dose levels of > 20 mg phenol/kg bw seem to be necessary to result in a 
production of quinones which is large enough to trigger toxicity. Therefore, in general it is concluded that 
the substances in this group of chemically defined flavouring substances may be expected to be metabolised 
to innocuous products at the estimated levels of intake. 
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ANNEX IV: TOXICITY 
Oral acute toxicity data are available for six candidate substances of the present flavouring group evaluation from chemical groups 21 and 25, and for 21 
supporting substances evaluated by JECFA at the 55th meeting (JECFA, 2001b). The supporting substances are listed in brackets. 
TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no]  Species  Sex  Route  LD50 
( mg/kg bw)  
Reference  Comments 
(2-Methylphenol [04.027]) Rat F Oral 1000 – 2000* (Pinkerton & Daniel, 1978) *Results are for the o-, m- and p-isomers. 
Rat NR Oral 121 (E.I. du Pont de Nemours & 
Company, 1969b) 
 
Rat M, F Gavage 300 (Bailey, 1983)  
Rat M, F Gavage 530 (Deichmann & Witherup, 
1944) 
Substance administered as a 2 % or 5 % aqueous solution. 
Rat M, F Gavage 540 (Deichmann & Witherup, 
1944) 
Substance administered as a 10 % aqueous solution. 
Rat M, F Gavage 340 (Deichmann & Witherup, 
1944) 
Substance administered as a 20 % aqueous solution. 
Rat F Gavage 400 (Berman et al., 1995)  
(3-Methylphenol [04.026]) Rat F Oral 1000 – 2000* (Pinkerton & Daniel, 1978) Results are for the o-, m- and p-isomers. 
Rat M Oral 242 (E.I. du Pont de Nemours & 
Company, 1969a) 
 
Rat M Gavage 520 (Carpenter, 1949b)  
(4-Methylphenol [04.028]) Rat F Oral 1000 – 2000* (Pinkerton & Daniel, 1978) Results are for the o-, m- and p-isomers. 
3-Ethylphenol [04.021] Rat M, F Oral M: 252  
F: 400 
(Eastman Kodak Co., 
1980b) 
 
(4-Ethylphenol [04.022]) Rat NR Oral >5000 (Blaszcak & Auletta, 1986)  
(2-Propylphenol [04.046]) Rat NR Oral 500 (Unigovski & Veldre, 
1975) 
 
(4-Propylphenol [04.050]) Mouse NR Oral 700 (Pellmont, 1973a)  
(4-(1,1-Dimethylethyl)phenol [04.064]) Rat M, F Gavage M: 5360  
F: 3620 
(Klonne et al., 1988)  
Rat M Gavage 3.25 ml/kg 
(3250) 
(Smyth et al., 1969a)  
Rat NR Oral ≈ 3500 (Zelle, 1982)  
Rat NR Oral 1400 (Palanker & Denine, 1973)  
Guinea  
pig 
NR Oral 1400* 
400** 
(Dow Chemical Company, 
1943) 
*Value = LD100 
**Value = LD0 
(p-Tolyl acetate [09.036]) Rat NR Oral 1900 (Palanker & Denine, 1973)  
2,3-Dimethylphenol [04.065] Rat NR Oral <5000 (De Cresente, 1982)  
(2,5-Dimethylphenol [04.019]) Rat NR Oral 444 (Maazik, 1968)  
(Veldre, 1972) 
 
Rat NR Gavage <5000 (De Cresente, 1982)  
Mouse NR Oral 383 (Maazik, 1968)  
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TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no]  Species  Sex  Route  LD50 
( mg/kg bw)  
Reference  Comments 
Rabbit NR Oral 938 (Maazik, 1968)  
(2,6-Dimethylphenol [04.042]) Rat NR Oral 296 (Maazik, 1968)  
Rat NR Oral 406 (Larionov, 1976)  
Mouse NR Oral 479 (Maazik, 1968)  
Mouse NR Oral 450 (Larionov, 1976)  
Rabbit NR Oral 700 (Maazik, 1968)  
(3,4-Dimethylphenol [04.048]) Rat NR Oral 727 (Maazik, 1968)  
Rat NR Oral 1600 (Eastman Kodak Co., 
1991c) 
 
Mouse NR Oral 400 (Maazik, 1968); 
(Eastman Kodak Co., 
1991c) 
 
Rabbit NR Oral 800 (Maazik, 1968)  
3,5-Dimethylphenol [04.020] Rat NR Oral 2250 (Uzhdavini et al., 1979)  
Rat NR Oral 608 (Maazik, 1968)  
Mouse NR Oral 477 (Maazik, 1968)  
Mouse M Gavage 620 (McOmie et al., 1949)  
Rabbit NR Oral 1313 (Maazik, 1968)  
5-Methyl-2-(tert-butyl)phenol [04.078] Mouse M Gavage 1080 (McOmie et al., 1949)  
(4-Vinylphenol [04.057]) Rat M, F Gavage >5000 (Piccirillo & Hartman, 
1982) 
 
(2-Methoxyphenol [04.005]) Rat M, F Gavage 725 (Taylor et al., 1964)  
Mouse NR Oral 621 (Cioli et al., 1980)  
4-Methoxyphenol [04.077] Rat M, F Gavage >5000 (Blaszcak & Auletta, 1987)  
(2,6-Dimethoxyphenol [04.036]) Rat M, F Oral 790 (Piccirillo & Hartman, 
1982) 
 
(4-Methyl-2,6-dimethoxyphenol [04.053]) Rat M, F Oral 1700 (Piccirillo & Hartman, 
1982) 
 
(4-Ethyl-2,6-dimethoxyphenol [04.052]) Rat M, F Oral 2300 (Piccirillo & Hartman, 
1982) 
 
(2,6-Dimethoxy-4-propylphenol [04.056]) Rat M, F Oral >5000 (Piccirillo & Hartman, 
1982) 
 
(4-Allyl-2,6-dimethoxyphenol [04.051]) Rat M, F Oral 2000 (Piccirillo & Hartman, 
1982) 
 
4-Hydroxyacetophenone [07.243] Mouse M Oral 1780 (Procter & Gamble 
Company, 1977) 
 
(4-(p-Hydroxyphenyl)butan-2-one [07.055]) Rat NR Oral >5000 (Mc Gee Laboratories, Inc., 
1974) 
 
Rat M, F Gavage M: 1320  
F: 1400 
(Gaunt et al., 1970)  
(Vanillyl acetone [07.005]) Rat NR Oral 2580 (Moreno, 1977ae)  
(4-(4-Acetoxyphenyl)butan-2-one [09.288]) Rat M, F Gavage <5000 (Sauer & Salem, 1980)  
M = Male. F = Female. NR = Not reported. 
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Subacute / subchronic / chronic / carcinogenic toxicity data are available for three candidate substance of the present flavouring group evaluation from 
chemical groups 21 and 25 and for ten supporting substances evaluated by JECFA at the 55th meeting (JECFA, 2001b). The supporting substances are listed in 
brackets. 
TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
(2-Methylphenol [04.027]) Mouse; M, F 
20 
Diet 0, 1250, 2500, 5000, 
10.000, 20.000 ppm 
(equal to M: 0, 199, 400, 
794, 1490, 2722 mg/kg 
bw; F: 0, 237, 469, 935, 
1663, 3205 mg/kg bw)  
13 weeks M: 199 
F: 496 
(NTP, 1992c) 5. 
Rat; M, F 
60 
Gavage 0, 50, 175, 600 mg/kg 
bw 
13 weeks 175 (EPA, 1988b) 5. 
Rat; M, F 
40 
Diet 0, 1880, 3750, 7500, 
15.000, 30.000 ppm 
(equal to M: 0, 126, 247, 
510, 1017, 2028 mg/kg 
bw; F: 0, 129, 256, 513, 
1021, 2004 mg/kg bw)  
13 weeks 250 (NTP, 1992c) 5. 
(3-Methylphenol [04.026]) Mouse; M, F 
20 
Diet 0, 625, 1250, 2500, 
5.000, 10.000 ppm 
(equal to M: 0, 96, 194, 
402, 776, 1513 mg/kg 
bw; F: 0, 116, 239, 472, 
923, 1693 mg/kg bw) 
13 weeks M: 4021 
F: 9231 
(NTP, 1992c) 5. 
Rat; M, F 
40 
Diet 0, 1880, 3750, 7500, 
15.000, 30.000 ppm 
(equal to M: 0, 123, 241, 
486, 991, 2014 mg/kg 
bw; F: 0, 131, 254, 509, 
1024, 2050 mg/kg bw) 
13 weeks 2501 (NTP, 1992c) 5. 
Rat; M, F 
24 
Gavage 0, 10, 30, 100, 300 
mg/kg bw 
Neonatal toxicity study:  
Postnatal days 
4 – 21 
Newborn:  
30 
(Koizumi et al., 2003) 5. 
Rat; M, F 
14 
Gavage 0, 100, 300, 1000 mg/kg 
bw 
28 days 300 (Koizumi et al., 2003) 5. 
(4-Methylphenol [04.028]) Mouse; M, F 
20 
Diet 0, 625, 1250, 2500, 
5.000, 10.000 ppm 
(equal to M: 0, 96, 194, 
402, 776, 1513 mg/kg 
bw; F: 0, 116, 239, 472, 
923, 1693 mg/kg bw) 
13 weeks M: 4021  
F: 9231 
(NTP, 1992c) 5. 
Rat; M, F 
60 
Gavage 0, 50, 175, 600 mg/kg 
bw 
13 weeks M: 50  
F: 175 
(EPA, 1988a) 5 
Rat; M, F 
40 
Diet 0, 1880, 3750, 7500, 
15.000, 30.000 ppm 
13 weeks 2501 (NTP, 1992c) 5 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
(equal to M: 0, 123, 241, 
486, 991, 2014 mg/kg 
bw; F: 0, 131, 254, 509, 
1024, 2050 mg/kg bw) 
Hamster; M 
15 
Diet 1,5 % 
(equivalent to 1600 
mg/kg bw) 
20 weeks No NOAEL derived (Hirose et al., 1986) 5. 
Induction of hyperplasia in forestomach. 
Only effects on forestomach studied. 
(4-Ethylphenol [04.022]) Rat; M, F 
20 – 32 
Diet M: 0.199 mg/kg bw 
F: 0.219 mg/kg bw 
90 days M: 0.199 
F: 0.219 
(Posternak et al., 1969) 5. 
 (4-(1,1-Dimethylethyl)phenol 
[04.064]) 
Hamster; M 
15 
Diet 1.5 % 
(equivalent to 1600 
mg/kg bw) 
20 weeks No NOAEL derived (Hirose et al., 1986) 5. 
Induction of hyperplasia in forestomach. 
Only effects on forestomach studied. 
2,4-Dimethylphenol [04.066] Rat; M, F 
20 – 32 
Gavage 0, 60, 180, 540 mg/kg 
bw 
90 days 60 (Daniel et al., 1993) Well conducted non GLP study. Significant 
findings were hyperkeratosis and hyperplasia 
of the forestomach in the two highest dose 
groups. 
(2,6-Dimethylphenol [04.042]) Rat; NR 
13 
Gavage 0.06 and 6.0 mg/kg bw 8 months 0.06 (Maazik, 1970) 5 
(3,4-Dimethylphenol [04.048]) Rat; NR 
13 
Gavage 0.14 and 14 mg/kg bw 8 months 0.14 (Maazik, 1970) 5 
(Thymol [04.006]) Rat; M, F 
10 
Diet 1000 and 10.000 ppm 
(equivalent to 50, 500 
mg/kg bw) 
19 weeks 500 (Hagan et al., 1967) 5 
4-Methoxyphenol [04.077] Rat; M, F 
20 
Diet 0, 0.02, 0.1, 0.5, 2 and 5 
% 
(equivalent to 0, 20, 
100, 500, 2000, 5000 
mg/kg bw)  
5 – 7 weeks 100 (Hodge et al., 1949) Study not in accordance with modern 
guidelines, no statistical evaluation. Only 
effect observed on body- and organ weight. 
Rabbit 
6 
Diet 0, 1 and 5 % 
(equivalent to 0, 300 
and 1500 mg/kg bw) 
5 – 9 weeks 300 (Hodge et al., 1949) Study not in accordance with modern 
guidelines, no statistical evaluation. Only 
effect observed on body- and organ weight. 
Rat; NR 
5 – 10 
Diet 2 % 
(equivalent to 2000 
mg/kg bw) 
4 – 8 weeks No NOAEL derived (Altmann et al., 1985; 
Altmann et al., 1986) 
Hyperplasia induced in all dosed animals.  
Only forestomach effects investigated. 
Hamster; M 
15 
Diet 1,5% 
(equivalent to 1600 
mg/kg bw) 
20 weeks No NOAEL derived (Hirose et al., 1986) Induction of hyperplasia in forestomach. 
Only effects on forestomach studied. 
Rat; M 
10 – 11 
Diet 0, 0.25, 0.5, 1 and 2 % 
(equivalent to 0, 125, 
250, 500 and 1000 
mg/kg bw) 
51 weeks  125 (Wada et al., 1990) Histological examination of liver, 
forestomach, stomach, esophagus and 
kidney. 
Rat; M 
10 - 11 
Diet 2 % 
(equivalent to 1000 
mg/kg bw) 
24 – 48 weeks No NOAEL derived (Kagawa et al., 1993) Hyperplasia induced in all dosed animals, no 
carcinomas. Only forestomach effects 
investigated. 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
Rat; M, F 
60 
Diet 2 % 
(equivalent to 1000 
mg/kg bw) 
104 weeks No NOAEL derived (Asakawa et al., 1994) The only dose of 2 %  tested induced 
hyperplasia, papillomas and squamos cell 
carcinomas  in the forestomach. Only effects 
on forestomach investigated. 
Rat; M 
30 – 31 
Diet 0.4 % 
(equivalent to 200 
mg/kg bw) 
104 weeks No NOAEL derived (Hirose et al., 1997) Study on induction of forestmach tumors. 
Reduced body weight in dosed animals. 
Increase in forestomach hyperplasia, no 
carcinomas. 
Rat; M 
10 – 15 
Diet 0.08 and 0.4 % 
(equivalent to 40 and 
200 mg/kg bw) 
24 weeks after 
4 weeks initiation 
40 (Hirose et al., 1997) Initiation with a combination of 
diethylnitrosamine, N-methylnitrosourea, 
1,2-dimethylhydrazine, N-butyl-N-(4-
hydroxybutyl)-nitrosamine and 2,2’-
dihydroxy-di-n-propylnitrosamine. All major 
organs were examined histopathologically. 
Increase in forestomach papillomas in 
highest dosed group. No carcinomas. 
(2,6-Dimethoxyphenol [04.036]) Rat; M, F 
20 – 32 
Diet M: 5.99 mg/kg bw 
F: 6.85 mg/kg bw 
90 days M: 5.992  
F: 6.85 
(Posternak et al., 1969) 5. 
3,4-Methylenedioxyphenol [04.080] Mouse; M, F 
60 
Diet 2 % 
(equivalent to 1000 
mg/kg bw) 
96 weeks No NOAEL derived (Tamano et al., 1992) Hematological and clinical biochemical  as 
well as histopathological examination of all 
major organs. Significant different findings 
were induction of  forestomach hyperplasia 
and squamous cell carcinomas in both males 
and females and hyperplasia in the glandular 
stomach in females only. 
Rat; M, F 
60 
Diet 2 % 
(equivalent to 1000 
mg/kg bw) 
104 weeks No NOAEL derived (Tamano et al., 1992) Hematological and clinical biochemical  as 
well as histopathological examination of all 
major organs. Significant different findings 
were induction of  forestomach hyperplasia 
and squamous cell carcinomas in both males 
and females. 
Rat; M 
10 - 11 
Diet 2 % 
(equivalent to 1000 
mg/kg bw) 
24 – 48 weeks No NOAEL derived (Kagawa et al., 1993) Hyperplasia induced in all dosed animals, no 
carcinomas. Only forestomach effects 
investigated. 
Rat; M 
30 - 31 
Diet 0.4 % 
(equivalent to 200 
mg/kg bw) 
104 weeks No NOAEL derived 
 
(Hirose et al., 1997) Study on induction of forestomach tumors. 
Reduced body weight in dosed animals. 
Increase in forestomach hyperplasia, no 
carcinomas. 
Rat; M 
10 - 15 
Diet 0.08 and 0.4 % 
(equivalent to 40 and 
200 mg/kg bw) 
24 weeks after 
4 weeks initiation 
200 (Hirose et al., 1997) Initiatioan with a combination of 
diethylnitrosamine, N-methylnitrosourea, 
1,2-dimethylhydrazine, N-butyl-N-(4-
hydroxybutyl)-nitrosamine and 2,2’-
dihydroxy-di-n-propylnitrosamine.  All 
major organs were examined 
histopathologically. No significant 
differences were observed. 
(4-(p-Hydroxyphenyl)butan-2-one Rat; M, F Diet 0, 0.1, 0.2, 0.4 and 1 % 13 weeks 100 (Gaunt et al., 1970) 5. 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no]  Species; Sex 
No./Group 
Route  Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
[07.055]) 30 (equivalent to 0, 50, 
100, 200 and 500 mg/kg 
bw) 
Valid study. Reduced body weight of males 
dosed 1 %.  Slight increase in relative weight 
of liver, adrenal and kidney in male  rats 
dosed 0.4 and 1 %. No difference between 
animals dosed 1 % and control animals in 
haematological, clinical chemical, urine  and 
histological examination. Histopathological 
examination therefore not conducted on the 
middle dosed groups. 
M = Male; F = Female. 
NR = Not reported. 
1 Administered as a mixture: m-cresol, 60 %; p-cresol, 40 %. 
2 This study was performed at either a single dose level or multiple dose levels that produced no adverse effects.  
3 NOAEL not determined. Study evaluated induction of fore stomach lesions and carcinogenicity.  
4 Did not act as a tumour promoter. 
5 Summarised by JECFA, 55th meeting (JECFA, 2001b). 
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Developmental and reproductive toxicity data are available for three candidate substances of the present flavouring group evaluation from chemical groups 21 
and 25 and for five supporting substance evaluated by the JECFA at the 55th meeting (JECFA, 2001b). Supporting substance listed in brackets. 
TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name [FL-no]  Study type 
Duration 
Species / Sex 
No / group 
Route  Dose levels NOAEL ( mg/kg bw/day), 
including inf. of possible 
maternal toxicity 
Reference Comments 
(2-Methylphenol [04.027]) Two generation Reproductive 
Toxicity: 5 days/week 
Rat; M, F 
50 
Gavage 30, 175 and 450 
mg/kg bw 
Parental: 30  
Offspring: 175 
(Tyl & Neeper-Bradley, 
1989a) 
2. 
Developmental Toxicity: Gestation 
Days 6 - 15 
Rat; F 
25 
Gavage 30, 175 and 450 
mg/kg bw 
Maternal: 175  
Foetal: 175 
(Tyl, 1988a) 2. 
Developmental Toxicity: Gestation 
Days 6 - 18 
Rabbit; F 
14 
Gavage 5, 50, 100 mg/kg 
bw 
Maternal: 5  
Foetal: 50 
(Tyl, 1988b) 2. 
(3-Methylphenol [04.026]) Two generation Reproductive 
Toxicity: 5 days/week 
Rat; M, F 
50 
Gavage 30, 175 and 450 
mg/kg bw 
Parental: < 30  
Offspring: 175 
(Tyl & Neeper-Bradley, 
1989b) 
2. 
RACB: (Task 1) 2 weeks Mouse; M, F 
 
Diet 370, 1500 and 
2100 mg/kg bw 
15001 (Heindel et al., 1992) 2. 
Number of animals not 
given, but may be known 
from the study design; 
(RACB protocol). 
RACB: (Task 2) 18 weeks Mouse; M, F 
 
Diet 370, 1500 and 
2100 mg/kg bw 
Reproductive: 3701 (Heindel et al., 1992) 2. 
Number of animals not 
given, but may be known 
from the study design; 
(RACB protocol). 
RACB: (Task 3) 14 weeks Mouse; M, F 
 
Diet 450, 1700 and 
2100 mg/kg bw 
< 17001 (Heindel et al., 1992) 2. 
Number of animals not 
given, but may be known 
from the study design; 
(RACB protocol). 
RACB: (Task 4) 32 weeks Mouse; M, F 
 
Lactation/diet 450, 1700 and 
2100 mg/kg bw 
< 4501 (Heindel et al., 1992) 2. 
Number of animals not 
given, but may be known 
from the study design; 
(RACB protocol). 
Developmental Toxicity: Gestation 
Days 6 - 15 
Rat; F 
25 
Gavage 30, 175 and 450 
mg/kg bw 
Maternal: 175  
Foetal: 450 
(Tyl, 1988a) 2. 
Developmental Toxicity: Gestation 
Days 6 - 18 
Rabbit; F 
14 
Gavage 5, 50 and 100 
mg/kg bw 
Maternal: 5  
Foetal: 100 
(Tyl, 1988b) 2. 
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TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name [FL-no]  Study type 
Duration 
Species / Sex 
No / group 
Route  Dose levels NOAEL ( mg/kg bw/day), 
including inf. of possible 
maternal toxicity 
Reference Comments 
(4-Methylphenol [04.028]) Two generation Reproductive 
Toxicity: 5 days/week 
Rat; M, F 
50 
Gavage 30, 175 and 450 
mg/kg bw 
Parental: 30  
Offspring: 175 
(Tyl & Neeper-Bradley, 
1989c) 
2. 
RACB: (Task 1) 2 weeks Mouse; M, F 
 
Diet 370, 1500 and 
2100 mg/kg bw 
21001 (Heindel et al., 1992) 2. 
Number of animals not 
given, but may be known 
from the study design; 
RACB. 
RACB: (Task 2) 18 weeks Mouse; M, F 
 
Diet 370, 1500 and 
2100 mg/kg bw 
Reproductive: 3701 (Heindel et al., 1992) 2. 
Number of animals not 
given, but may be known 
from the study design; 
RACB. 
RACB: (Task 3) 14 weeks Mouse; M, F 
 
Diet 450, 1700 and 
2100 mg/kg bw 
< 21001 (Heindel et al., 1992) 2. 
Number of animals not 
given, but may be known 
from the study design; 
RACB. 
RACB: (Task 4) 32 weeks Mouse; M, F 
 
Lactation/diet 450, 1700 and 
2100 mg/kg bw 
< 4501 (Heindel et al., 1992) 2. 
Number of animals not 
given, but may be known 
from the study design; 
RACB. 
Developmental Toxicity: Gestation 
Days 6 - 15 
Rat; F 
25 
Gavage 30, 175 and 450 
mg/kg bw 
Maternal: 175  
Foetal: 175 
(Tyl, 1988a) 2. 
Developmental Toxicity: Gestation 
Day 11 
Rat; F 
13 
Gavage 100, 333, 667 and 
1000 mg/kg bw 
Maternal: 100  
Foetal: 1000 
(Kavlock, 1990) 2. 
Developmental Toxicity: Gestation 
Days 6 - 18 
Rabbit; F 
3/14 
Gavage 5, 50 and 100 
mg/kg bw 
Maternal: 5  
Foetal: 100 
(Tyl, 1988b) 2. 
(Thymol [04.006]) Developmental Toxicity: Gestation 
Days 19 - 26 
Rabbit; F 
3 
Gel capsule  < 294 (Savignoni & de Maria, 1933) 2. 
3-Methoxyphenol [04.076] Developmental Toxicity: Gestation 
Day 11 
Rat; F 
16 
Gavage 0, 333, 667, 1000 
mg/kg bw 
Maternal: < 333  
Foetal: 1000 
(Kavlock, 1990) The study is considered 
valid. 
4-Methoxyphenol [04.077] Developmental Toxicity: Gestation 
Day 11 
Rat; F 
16 
Gavage 0, 333, 667, 1000 
mg/kg bw 
Maternal: <333  
Foetal: 1000 
(Kavlock, 1990) The study is considered 
valid. 
(4-Ethoxyphenol [04.037]) Developmental Toxicity: Gestation 
Day 11 
Rat; F 
15 
Gavage 0, 333, 667, 1000 
mg/kg bw 
Maternal: 333  
Foetal: 1000 
(Kavlock, 1990) 2. 
The study is considered 
valid.  
4-Hydroxyacetophenone [07.243] Developmental Toxicity: Gestation 
Day 11 
Rat; F 
16 
Gavage 0, 333, 667, 1000 
mg/kg bw 
Maternal: 1000  
Foetal: 667 
(Kavlock, 1990) The study is considered 
valid. 
M = Male; F = Female. 
NR = Not reported. 
RACB = Reproductive and fertility assessment by continuous breeding. 
Task 1 = Dose range-finding phase. 
Task 2 = Continuous breeding phase. Mice were exposed to the test article for a 7-day premating phase, 98-day cohabitation period and a 21-day segregation period. 
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Task 3 = Crossover mating trial. Mice were exposed to the test article for a 7-day premating period, followed by a 14-week cohabitation/breeding period.  
Task 4 = Offspring reproductive performance phase. 
1) Study evaluated a mixture of m- and p-cresol. 
2) Summarised by JECFA, 55th meeting (JECFA, 2001b). 
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In vitro mutagenicity/genotoxicity data are available for 12 candidate substances of the present flavouring group evaluation from chemical groups 21 and 25 
and for 18 supporting substances evaluated by JECFA at the 55th meeting (JECFA, 2001b). Supporting substances are listed in brackets. 
TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
(2-Methylphenol [04.027]) Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
2.5 µl/plate 
(26,200µg/plate) 
Negative1, 2 (Douglas et al., 1980) 17. 
Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
324 µg/plate Negative1, 2 (Florin et al., 1980) 17. 
Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
5 concentrations from 
1 to 100 µg/plate 
Negative1, 2 (Haworth et al., 1983) 17. 
Acceptable quality. Published summary report 
including detailed results from studies on 250 
chemicals tested in various laboratories within 
the NTP. In accordance with OECD guideline 
471 (1983). 
Ames assay S. typhimurium  
TA98; TA100 
5 µg/plate Negative1, 2 (Massey et al., 1994) 17. 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
Up to 2600 µg/plate 
(range not reported) 
Negative1, 2, 3 (Nestmann et al., 1980) 17. 
Insufficient quality as main details of method 
and results were not reported. Additionally, the 
test was not repeated. 
Ames assay S. typhimurium  
TA98; TA100; TA1535; 
TA1537; TA1538 
4 concentrations from 
5 to 5000 µg/plate 
Negative1, 2 (Pool & Lin, 1982) 17. 
Acceptable quality. 
Ames assay 
(preincubation assay) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
1000 µg/plate Negative1, 2 (Canter, 1981) 17. 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
500 µg/plate Negative1, 2 (Nuodex Inc., 1980a) 17. 
Ames assay S. typhimurium  
TA98; TA100 
Not reported Negative4 Positive5 (Claxton, 1985) 17. 
Result cannot be evaluated since it was 
reported only as a very short summary in table 
format. The paper was on methodological 
aspects of the assay and not specifically on this 
compound. 
Sister chromatid exchange Human lymphocytes 5 concentrations up to 
0.5 mM (54 µg/ml) 
Negative (Jansson et al., 1986; Jansson 
et al., 1988) 
17. 
Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
Sister chromatid exchange Human fibroblasts 86.5 - 865 µg/ml 
without S9 
Equivocal (Cheng & Kligerman, 1984) 17. 
Limited quality. Only the highest 
concentration resulted in a result statistically 
significantly different from control (1.2-fold 
increase only). A second experiment was not 
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performed. 
Sister chromatid exchange Chinese Hamster ovary cells 4 concentrations from 
12.5 to 75 nl/ml 
(78.6 µg/ml) without 
S9, 
11 concentrations from 
1.56 to 700 nl/ml (733 
µg/ml) with S9 
Positive1 Positive2 (Galloway & Brusick, 1981) 17. 
Acceptable quality. Statistically significant 
dose-related increase (up to two-fold). 
Sister chromatid exchange Chinese hamster  
ovary cells 
Up to 500 nl/ml 
(524 µg/ml)4 
Positive1, 2 (Galloway & Brusick, 1980) 17. 
Acceptable quality but limited relevance 
because the test material was a mixture of p-
cresol, m-cresol and o-cresol (33 1/3 % each). 
Unscheduled DNA synthesis Rat primary hepatocytes 7 concentrations from 
0.5 to 50 nl/ml 
(52.4 µg/ml)4 
Equivocal (Myhr & Brusick, 1980) 17 . 
Acceptable quality but limited relevance 
because the test material was a mixture of p-
cresol, m-cresol and o-cresol (33 1/3 % each). 
Response was not dose-related. A slight 
response was observed at concentrations up to 
5.0 nl/ml, while UDS was not observed at 
concentrations from 10 to 50 nl/ml.  
DNA Repair assay E. coli W3110 5000 µg/ml Negative1, 2 (Pepper Hamilton & Scheetz, 
1980) 
17. 
Test substance included 60 % o-cresol. 
DNA repair assay E. coli 5000 µg/ml Negative1, 2 (Nuodex Inc., 1980b) 17. 
(3-Methylphenol [04.026]) Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
2000 µg/plate Negative1, 2 (Douglas et al., 1980) 17. 
Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
324 µg/plate Negative1, 2 (Florin et al., 1980) 17. 
Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Ames assay S. typhimurium 
TA98; TA100; TA1535;  
TA1537 
5 concentrations from 
3.3 to 333 µg/plate 
Negative1, 2 (Haworth et al., 1983) 17. 
Acceptable quality. Published summary report 
including detailed results from studies on 250 
chemicals tested in various laboratories within 
the NTP. In accordance with OECD guideline 
471 (1983). 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
Up to 2000 µg/plate 
(range not reported) 
Negative1, 2, 3 (Nestmann et al., 1980) 17. 
Insufficient quality as main details of method 
and results were not reported. Additionally, the 
test was not repeated. 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
5 concentrations from 
0.5 to 5000 µg/plate 
Negative1, 2 (Pool & Lin, 1982)  17. 
Acceptable quality. 
Ames assay 
(preincubation assay) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
3333 µg/plate Negative1, 2 (Canter, 1981)  17. 
Sister chromatid exchange Human lymphocytes 5 concentrations up to Negative (Jansson et al., 1986); 17. 
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1 mmol/L (108 µg/ml) (Jansson et al., 1988)  Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
Sister chromatid exchange Human fibroblasts 865 µg/ml Negative (Cheng & Kligerman, 1984)  17. 
Sister chromatid exchange Chinese hamster ovary cells Up to 500 nl/ml 
(524 µg/ml)4 
Positive1, 2 (Galloway & Brusick, 1980) 17. 
Acceptable quality but limited relevance 
because the test material was a mixture of p-
cresol, m-cresol and o-cresol (33 1/3 % each). 
Unscheduled  
DNA synthesis 
Rat primary hepatocytes 10 µg/ml Negative (Cifone, 1988a) 17. 
Unscheduled  
DNA synthesis 
Rat primary hepatocytes 7 concentrations from 
0.5 to 50 nl/ml 
(51.7 µg/ml)4 
Equivocal (Myhr & Brusick, 1980)  17. 
Limited relevance because the test material 
was a mixture of p-cresol, m-cresol and o-
cresol (33 1/3 % each). Response was not 
dose-related. A slight response was observed 
at concentrations up to 5.0 nl/ml, while UDS 
was not observed at concentrations from 10 to 
50 nl/ml.  
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(4-Methylphenol [04.028]) Ames assay S. typhimurium  
TA98; TA100; TA1535; 
TA1537; TA1538 
1000 µg/plate Negative1, 2 (Douglas et al., 1980) 17. 
Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
324 µg/plate Negative1, 2 (Florin et al., 1980) 17. 
Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
5 concentrations from 
3.3 to 333 µg/plate 
Negative1, 2 (Haworth et al., 1983) 17. 
Acceptable quality. Published summary report 
including detailed results from studies on 250 
chemicals tested in various laboratories within 
the NTP. In accordance with OECD guideline 
471 (1983). 
Ames assay S. typhimurium  
TA98; TA100 
5 µg/plate Negative1, 2 (Massey et al., 1994) 17. 
Ames assay S. typhimurium  
TA98; TA100; TA1535; TA1537; 
TA1538 
Up to 1000 µg/plate 
(range not reported) 
Negative1, 2, 3 (Nestmann et al., 1980) 17. 
Insufficient quality as main details of method 
and results were not reported. Additionally, the 
test was not repeated. 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
5 concentrations from 
0.5 to 5000 µg/plate 
Negative1, 2 (Pool & Lin, 1982) 17. 
Acceptable quality. 
Ames assay 
(preincubation assay) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
1000 µg/plate Negative1, 2 (Canter, 1981) 17. 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
1 µl/plate 
(1030 µg/plate) 
Negative1, 2 (Crowley & Margard, 1978) 17. 
Sister chromatid exchange Human lymphocytes 5 concentrations up to 
0.5 mmol/L (54 µg/ml) 
Negative (Jansson et al., 1986) 17. 
Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
Sister chromatid exchange Human fibroblasts 865 µg/ml Negative (Cheng & Kligerman, 1984) 17. 
Sister chromatid exchange Chinese hamster ovary cells Up to 500 nl/ml 
(524 µg/ml)4 
Positive1, 2 (Galloway & Brusick, 1980) 17. 
Acceptable quality but limited relevance 
because the test material was a mixture of p-
cresol, m-cresol and o-cresol (33 1/3 % each). 
Unscheduled DNA synthesis Human lymphocytes 25 µM 
(2.7 µg/ml) 
Negative (Daugherty & Franks, 1986) 17. 
Not relevant since only an inhibition of UV-
induced UDS was measured.. Additionally, a 
result is reported only for one concentration 
(resulting in inhibition by 30 %) and a 
negative control was not included. 
Unscheduled DNA synthesis Rat primary hepatocytes 7 concentrations from 
0.5 to 50 nl/ml 
(51.5 µg/ml) 
Equivocal (Myhr & Brusick, 1980) 17. 
Acceptable quality but limited relevance 
because the test material was a mixture of p-
cresol, m-cresol and o-cresol (33 1/3 % each). 
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Response was not dose-related. A slight 
response was observed at concentrations up to 
5.0 nl/ml, while UDS was not observed at 
concentrations from 10 to 50 nl/ml. 
Unscheduled DNA synthesis WI-38 human embryonic lung fibroblast 
cells 
Not unambiguously 
reported 
Positive (Crowley & Margard, 1978) 17. 
Unpublished study report of limited  quality 
because concentrations were not 
unambiguously reported and only 3 
concentrations have been tested. However, the 
result was reproducible. Liquid scintillation 
counting.  
2-Ethylphenol [04.070] Ames assay 
(preincubation method) 
S. typhimurium  
TA97; TA98; TA100; TA1535 
5 doses from 0.01 to 
10 mg/plate 
Negative1, 2 (Zeiger et al., 1992) Acceptable quality. 
Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
3 µmol/plate 
(367 µg/plate) 
Negative1, 2 (Florin et al., 1980) Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Sister chromatid exchange Human lymphocytes 5 concentrations up to 
0.25 mmol/L 
(30.5 µg/ml) 
Negative6 (Jansson et al., 1986) Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
3-Ethylphenol [04.021] Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535; TA1537 
3 µmol/plate 
(366 µg/plate) 
Negative1, 2 (Florin et al., 1980) Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Sister chromatid exchange Human lymphocytes 5 concentrations up to 
0.25 mmol/L 
(30.5 µg/ml) 
Negative6 (Jansson et al., 1986) Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
(4-Ethylphenol [04.022]) Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
367 µg/plate Negative1, 2 (Florin et al., 1980) 17. 
Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Ames assay  S. typhimurium  
TA98; TA100 
Not reported Negative1, 2 (Epler et al., 1979) 17. 
Insufficient quality. Not in accordance with 
OECD guideline 471. Only two strains tested. 
Results not reported in detail. 
Sister chromatid exchange Human lymphocytes 5 concentrations up to 
0.25 mmol/L  
(27 µg/ml) 
Negative (Jansson et al., 1986) 17. 
Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
(4-(1,1-Dimethyl)ethyl phenol 
[04.064]) 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
2000 µg/plate Negative1, 2 (Dean et al., 1985) 17. 
Insufficiently reported. Validity cannot be 
evaluated as the results were not reported in 
detail. 
Mutation assay E. coli WP2 and WP2 uvrA 2000 µg/plate Negative1, 2 (Dean et al., 1985) 17. 
Insufficiently reported. Validity cannot be 
evaluated as main details of the method (e.g. 
concentration range tested) were not reported. 
Additionally, the result was not reported in 
detail. 
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Mutation assay S. cerevisiae  
JD1 
2000 µg/plate Negative1, 2 (Dean et al., 1985) 17. 
Insufficiently reported. Validity cannot be 
evaluated as main details of the method (e.g. 
concentration range tested) were not reported. 
Additionally, the result was not reported in 
detail. 
Chromosomal aberration 
assay 
Rat liver cell RL1, RL2 Not specifically 
indicated7 
Negative (Dean et al., 1985) 17. 
Insufficiently reported. Validity cannot be 
evaluated as main details of the method (e.g. 
concentrations tested) were not reported. 
Additionally, the result was not reported in 
detail. 
Chromosome aberration assay Chinese hamster lung cells Not reported Negative8 (Kusakabe et al., 2002) 17. 
Mouse lymphoma assay L5178Y tk +/-  
mouse lymphoma cells 
80 µg/ml Negative (Honma et al., 1999b) 17. 
2,3-Dimethylphenol [04.065] Ames assay S. typhimurium  
TA98; TA100 
Not reported Negative1, 2 (Epler et al., 1979) Insufficient quality. Not in accordance with 
OECD guideline 471. Only two strains tested. 
Results not reported in detail. 
Sister chromatid exchange Human lymphocytes 5 concentrations up to 
0.5 mmol/L 
(61 µg/ml) 
Negative6 (Jansson et al., 1986) Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
2,4-Dimethylphenol [04.066] Ames assay 
(preincubation method) 
S. typhimurium  
TA97; TA98; TA100;  
TA1535; TA1537 
0, 0.33, 1, 3.3, 10, 33 
µg/plate 
Negative1, 2 (Mortelmans et al., 1986) Acceptable quality. 
Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
3 µmol/plate9
(366 µg/plate) 
Negative1, 2 (Florin et al., 1980) Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
5 concentrations from 
0.5 to 5000 µg/plate10 
Negative1, 2 (Pool & Lin, 1982) Acceptable quality. 
Sister chromatid exchange Human lymphocytes 5 concentrations up to 
0.1 mmol/L 
(12 µg/ml) 
Negative6 (Jansson et al., 1986) Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
(2,5-Dimethylphenol [04.019]) Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
367 µg/plate Negative1, 2 (Florin et al., 1980) 17. 
Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Ames assay S. typhimurium  
TA98; TA100 
Not reported Negative1, 2 (Epler et al., 1979) 17. 
Insufficient quality. Not in accordance with 
OECD guideline 471. Only two strains tested. 
Results not reported in detail. 
(2,6-Dimethylphenol [04.042]) Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
367 µg/plate Negative1, 2 (Florin et al., 1980) 17 
Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
5 mg/plate 
(5000 µg/plate) 
Negative1, 2 (Schechtman et al., 1980) 17. 
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TA1537; TA1538 
Chromosome aberration assay  Chinese hamster V79 cells 3 concentrations from 
10 to 100 µg/ml 
(without S9) and 5 
concentrations from 30 
to 600 µg/ml (with S9) 
Negative1 Positive2 (Völkner, 1994) 17. 
Acceptable quality. This GLP-study was in 
accordance with OECD guideline 473 (1983). 
A final report was not available and the draft 
was not signed. However, the results and 
conclusions available as draft report are 
considered valid. 
Sister chromatid exchange Human lymphocytes 5 concentrations up to 
0.25 mmol/L  
(31 µg/ml) 
Negative (Jansson et al., 1986) 17. 
Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
(3,4-Dimethylphenol [04.048]) Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
367 µg/plate Negative1, 2 (Florin et al., 1980) 17. 
Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Ames assay S. typhimurium  
TA98; TA100 
Not reported Negative1, 2 (Epler et al., 1979) 17. 
Insufficient quality. Not in accordance with 
OECD guideline 471. Only two strains tested. 
Results not reported in detail. 
3,5-Dimethylphenol [04.020] Ames assay 
(plate incorporation, 
preincubation, spot test, and 
treat-and-plate methods) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538;  
E. coli  
WP2; WP2uvrA 
6 concentrations from 
125 to 4000 µg/plate 
Negative1, 2 (Dean et al., 1985) Insufficiently reported. Validity cannot be 
evaluated as the results were not reported in 
detail. 
Mitotic gene conversion 
assay  
S. cerevisiae JD1  
 
Not reported Negative1, 2 (Dean et al., 1985) Insufficiently reported. Validity cannot be 
evaluated as main details of the method (e.g. 
concentration range tested) were not reported. 
Additionally, the result was not reported in 
detail. 
Chromosome aberration assay Rat liver cells RL4 3 concentrations from 
0.125 to 0.5 of GI50 
(50% growth 
inhibition). Values in 
µg/ml or µmol/ml not 
reported. 
Negative1, 2 (Dean et al., 1985) Insufficiently reported. Validity cannot be 
evaluated as main details of the method (e.g. 
concentrations tested) were not reported. 
Additionally, the result was not reported in 
detail. 
2,4,6-Trimethylphenol [04.095] Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
3 µmol/plate10
(409 µg/plate) 
Negative1, 2 (Florin et al., 1980) Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Ames assay S. typhimurium  
TA98; TA100 
Not reported Negative1, 2 (Epler et al., 1979) Insufficient quality. Not in accordance with 
OECD guideline 471. Only two strains tested. 
Results not reported in detail. 
(Thymol [04.006]) Ames assay S. typhimurium  
TA97; TA98; TA100 
1000 µg/ml Negative1, 2 (Azizan & Blevins, 1995) 17. 
Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537;  
TA1538 
451 µg/plate Negative1, 2 (Florin et al., 1980) 17. 
Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
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Ames assay 
(preincubation method) 
S. typhimurium  
TA97; TA98; TA100 
Not reported Negative1, 2 (Azizan & Blevins, 1995) 17. 
Sister chromatid exchange SHE cells 5 concentrations from 
0.3 to 30 µg/ml 
Equivocal (Fukuda, 1987) 17 . 
Validity cannot be evaluated since the study 
was published in Japanese (e.g. presence or 
absence of S9 is not clear). However, the 
results reported in a table were not dose-
related. 
Unscheduled DNA synthesis SHE cells 4 concentrations from 
0.3 to 10 µg/ml 
Equivocal (Fukuda, 1987) 17. 
Validity cannot be fully evaluated since the 
study was published in Japanese (e.g. presence 
or absence of S9 is not clear). However, the 
results reported in a table were not dose-
related. 
(Carvacrol [04.031]) Ames assay S. typhimurium  
TA98; TA100 
2 concentrations (8 
and 16 ppm) 
Negative1, 2 (Kono et al., 1995) 17. 
Not in accordance with OECD guideline 471 
(only two strains used and only two 
concentrations tested). In Japanese with a short 
summary in English. 
Ames assay 
(plate incorporation assay) 
S. typhimurium  
TA98; TA100 
3 concentrations from 
0.6 to 2.5 µmol/plate 
Negative1, 2 (Stammati et al., 1999) 17. 
This study was not in accordance with OECD 
guideline 471 (only two strains used and only 
3 concentrations tested). 
Bacterial DNA repair test E. coli  
WP2 trpE65; CM8781 
trpE65; uvrA155, 
 recA56, lexA 
4 concentrations from 
2.5 to 6 µmol/paper 
disk 
Positive (Stammati et al., 1999) 17. 
Effects were measured as inhibition zones. 
This assay is considered to be of minor 
relevance. Positive results from such assays 
may be interpreted as an indication of a 
genotoxic potential which needs to be clarified 
by other assays. 
SOS Chromotest E. coli PQ37 4 concentrations (not 
unambiguously 
reported) 
Negative (Stammati et al., 1999) 17. 
Concentrations not unambiguously reported, 
only without S9 tested. This assay is 
considered to be of minor relevance. Positive 
results from such assays may be interpreted as 
an indication of a genotoxic potential which 
needs to be clarified by other assays. 
(4-Vinylphenol [04.057]) Sister chromatid exchange Human lymphocytes 5 concentrations up to 
0.1 mmol/L  
(12 µg/ml) 
Negative (Jansson et al., 1988) 17. 
Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
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(2-Methoxyphenol [04.005]) 
 
 
Ames assay S. typhimurium  
TA98; TA100; TA102 
111,726 µg/plate Negative1, 2 (Aeschbacher et al., 1989) 17. 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
16,000 µg/plate Negative1, 2 (Douglas et al., 1980) 17. 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
5 concentrations from 
333 to 11,740 µg/plate 
in one experiment and 
5 concentrations from 
33 to 3333 µg/plate in 
two further 
experiments performed 
in another laboratory 
Negative1, 2 (Haworth et al., 1983) 17. 
Acceptable quality. Published summary report 
including detailed results from studies on 250 
chemicals tested in various laboratories within 
the NTP. Three experiments performed in two 
laboratories. In accordance with OECD 
guideline 471 (1983). 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
Up to 16,000 µg/plate 
(range not reported) 
Negative1, 2 (Nestmann et al., 1980) 17. 
Insufficient quality as main details of method 
and results were not reported. Additionally, the 
test was not repeated. 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
5 conentrations from 
0.5 to 5000 µg/plate 
Negative1, 2 (Pool & Lin, 1982) 17. 
Acceptable quality. 
Sister chromatid exchange Human lymphocytes 5 concentration up to 
0.5 mmol/L  
(62 µg/ml) 
Positive (Jansson et al., 1988) 17. 
Acceptable quality. Only the highest 
concentration resulted in a statistically 
significant increase. The effect was very waek 
but reproducible. 
3-Methoxyphenol [04.076] Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
30 µmol/plate 
(3724 µg/plate) 
Negative1, 2 (Florin et al., 1980) Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Sister chromatid exchange Human lymphocytes 5 concentrations up to 
1 mmol/L 
(124 µg/ml) 
Negative6 (Jansson et al., 1986) Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
4-Methoxyphenol [04.077] Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
5 concentrations from 
3.3 to 167 µg/plate in 
the first experiment 
and 5 concentrations 
from 100 to 5000 
µg/plate in the second 
experiment performed 
in another laboratory 
Negative2,  (Haworth et al., 1983) Acceptable quality. Published summary report 
including detailed results from studies on 250 
chemicals tested in various laboratories within 
the NTP. Experiments performed in two 
laboratories. In accordance with OECD 
guideline 471 (1983). 
Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
30 µmol/plate 
(3724 µg/plate) 
Negative1, 2 (Florin et al., 1980) Not in accordance with OECD guideline 471. 
Inadequate study design (Spot test). 
Ames assay 
(plate incorporation method) 
S. typhimurium TA100; TA1530 Up to 4 µmol/plate Negative1, 2, 12 (Bartsch et al., 1980) As only two strains were used the quality of 
the study must be considered insufficient for 
the purpose of this Flavouring Group 
Evaluation Validity cannot be evaluated as 
details of the result were not reported. 
Mouse lymphoma assay Mouse L5178Y TK +/- lymphocytes 27 to 2000 µg/ml Positive1 (Rogers-Back, 1986) The validity of this unpublished report cannot 
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TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-no]  Test System Test Object  Concentration Result  Reference  Comments 
(without S9) 
1.3 to 100 µg/ml (with 
S9) 
Negative2 fully be evaluated since all pages in table 
format are lacking. 
Sister chromatid exchange Human lymphocytes 5 concentrations up to 
0.05 mmol/L 
(6.2 µg/ml) 
Negative6 (Jansson et al., 1986) Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
Chromosome aberration assay Chinese hamster ovary cells 954, 1269, and 1692 
µg/ml (each in the 
presence and absence 
of S9) 
Positive1, 2 (Putman, 1986) The validity of this unpublished report cannot 
fully be evaluated since all pages in table 
format are lacking. 
Unscheduled DNA synthesis Human lymphocytes 25 µM 
(3.1 µg/ml) 
Equivocal (Daugherty & Franks, 1986) Not relevant since only an inhibition of UV-
induced UDS was measured. Additionally, a 
result is reported only for one concentration 
(resulting in inhibition by 30 %) and a 
negative control was not included. 
(2-Methoxy-4-methylphenol 
[04.007]) 
Sister chromatid exchange Human lymphocytes 5 concentrations up to 
1 mmol/L 
(138 µg/ml) 
Positive (Jansson et al., 1988) 17. 
Acceptable quality. The effect was weak 
(twofold increase) but dose-related and 
statistically significant. 
(4-Ethylguaiacol [04.008]) Sister chromatid exchange Human lymphocytes 5 concentration up to 1 
mmol/L 
(152 µg/ml) 
Negative (Jansson et al., 1988) 17. 
Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
(2,6-Dimethoxyphenol [04.036]) Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
16,000 µg/plate Negative (Douglas et al., 1980) 17. 
Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
463 µg/plate Negative1, 2 (Florin et al., 1980) 17. 
Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
1000 µg/ml Negative1, 2 (McMahon et al., 1979) 17. 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
5 concentrations from 
0.5 to 5000 µg/plate 
Negative1, 2 (Pool & Lin, 1982) 17. 
Acceptable quality. 
Mutation assay E. coli 1000 µg/ml Negative1, 2 (McMahon et al., 1979) 17. 
Sister chromatid exchange Human lymphocytes 4 concentrations up to 
0.5 mmol/L 
(77 µg/ml) 
Negative (Jansson et al., 1986) 17. 
Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated).  
4-Hydroxy-3,5- 
dimethoxyacetophenone [07.164] 
Ames assay 
(plate incorporation assay) 
S. typhimurium  
TA97; TA98; TA100; TA102 
6 concentrations from 
10 to 4000 µg/plate 
Negative1, 2 (Pfuhler et al., 1995) Limited quality. Strain TA 1535 was not used 
although recommended by OECD 471 (1983 
and 1997) which may be acceptable but the 
test was not repeated. 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
Up to 1 mg/plate 
(range not reported) 
Negative1, 2 (Nestmann et al., 1980) Insufficient quality as main details of method 
and results were not reported. Additionally, the 
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TA1537; TA1538 test was not repeated. 
Mutagenicity assay S. cerevisiae D7; XV185-14C Not reported Negative1 (Nestmann & Lee, 1983) Insufficient quality. Details of concentrations 
and results not reported. 
Sister chromatid exchange Human peripheral lymphocytes 4 concentrations from 
3.3 to 100 µg/ml 
Negative1, 2 (Pfuhler et al., 1995) Limited quality as the test was not repeated in 
an independent experiment. Otherwise in 
accordance with OECD 479 (1986). 
(2-Methoxy-4-vinylphenol [04.009]) Sister chromatid exchange Human lymphocytes 5 concentrations up to 
0.5 mmol/L 
(75 µg/ml) 
Equivocal (Jansson et al., 1988) 17. 
Limited quality (selection of maximum 
concentration not justified and experiment not 
repeated). Weak effect (only the highest 
concentration resulted in a twofold increase of 
SCE frequency which was statistically 
significant but was not repeated in a second 
experiment).  
3,4- Methylenedioxyphenol [04.080] Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA102 
4 concentrations from 
1 to 10 µM/plate 
(1381 µg/plate) 
(Not applicable)13 (Kaur & Saini, 2000) Limited relevance. Antimutagenic activity was 
investigated only. The substance was tested 
only in combination with mutagens. 
Ames Assay 
(plate incorporation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
33 - 3333 µg/plate Negative1, 2, 14 (Longfellow, 1985/1986) Validity cannot be evaluated. The information 
was generated from the Chemical 
Carcinogenesis Research Information System 
database. Details of methods and results were 
not available. 
Mouse lymphoma assay Mouse L5178Y TK +/- lymphocytes 25 - 215 µg/ml Positive1, 2 (Longfellow, 1985/1986) Validity cannot be evaluated. The information 
was generated from the CCRIS database. 
Details of methods and results were not 
available. 
(2-Hydroxyacetophenone [07.124]) Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
408 µg/plate Negative1, 2 (Florin et al., 1980) 17. 
Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
4- Hydroxy acetophenone [07.243] Ames assay 
(preincubation method) 
S. typhimurium  
TA98; TA100; TA1535;  
TA1537 
 
30 µmol/plate 
(4085 µg/plate) 
Negative1, 2 (Florin et al., 1980) Insufficient quality. Not in accordance with 
OECD guideline 471. Inadequate study design 
(Spot test). 
Acetovanillone [07.142] Ames assay 
(preincubation and plate 
incorporation methods) 
S. typhimurium  
TA98; TA100 
Not reported Negative1, 2 (Xu et al., 1984) Insufficient quality. Not in accordance with 
OECD guideline 471. Only two strains used. 
Concentration range not reported. Details of 
results not reported. 
Ames assay S. typhimurium  
TA98; TA100; TA1535;  
TA1537; TA1538 
Up to 1 mg/plate 
(range not reported) 
Negative1, 2 (Nestmann et al., 1980) Insufficient quality as main details of method 
and results were not reported. Additionally, the 
test was not repeated. 
Mutagenicity assay S. cerevisiae D7;  
S. cerevisiae XV185-14C 
6 concentrations from 
100 to 1000 µg/ml 
Negative15 
Positive15 
(Nestmann & Lee, 1983) Tested only without S9, however the positive 
results reported seem to be reliable. 
(Vanillyl acetone [07.005]) Ames assay 
(plate incorporation method) 
S. typhimurium  
TA98; TA100 
1000 µg/plate Negative2, 16 (Mikulasova & Bohovicova, 
2000) 
17. 
DNA Repair test E. coli  
WP2, WP2uvrA, CM611;  
2000 µg/ml Negative (Mikulasova & Bohovicova, 
2000) 
17. 
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CM561 
GI = Growth inhibition. 
IP = Intraperitoneal. 
1) Without metabolic activation. 
2 ) With metabolic activation. 
3) Presumably non-mutagenic but solubility did not allow testing in amounts that result in lethality. 
4) Negative results in TA100, with and without S9 metabolic activation. 
5) Positive results in TA98, with and without metabolic activation. 
6) The use of metabolic activation was not reported. 
7) The concentrations selected for this assay corresponded to 0.5, 0.25, and 0.125 of the concentration causing 50 % growth inhibition (this concentration was not specified) as determined from a 
cytotoxicity assay. 
8) Test substance was negative in a short-term assay without S9 metabolic activation and in a long-term assay (48 hours.) with and without S9 metabolic activation. The test substance gave 
positive results in the short-term assay with S9 metabolic activation. 
9) Tested quantitatively with TA100. Substance was cytotoxic at 30 µmol/plate. 
10) 5000 µg/plate resulted in cytotoxicity which was defined as a thinning of the background lawn. 
11) Tested quantitatively with TA98. Substance was cytotoxic at 30 µmol/plate. 
12) The presentation of the result in the publication obviously led the petitioner to the interpretion that the substance was positive in TA1530 but this is not correct. From the footnotes of the 
publication it becomes clear that the substance was tested  in TA100 and TA1530 and that the result was negative. However, as only two strains were used the quality of the study must be 
considered insufficient for the purpose of this Flavouring Group Evaluation. 
13) Antimutagenicity study. Sesamol greatly reduced the mutagenic effects of t-BOOH. 
14) Test with both rat and mouse S-9 metabolic activation. 
15) Negative response for gene conversion (strain D7) and a positive response for reversion (strain XV185-14C). 
16) Dose level was the highest non-toxic dose level examined. At 2500 µg/ml cytotoxicity was observed. 
17) Summarised by JECFA, 55th meeting (JECFA, 2001b). 
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In vivo mutagenicity/genotoxicity data are available for one candidate substance of the present flavouring group evaluation from chemical groups 21 and 25 
and for four supporting substances evaluated by the JECFA at the 55th meeting (JECFA, 2001b). Supporting substances are listed in brackets.  
TABLE IV.5: GENOTOXICITY (IN VIVO) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
(2-Methylphenol [04.027]) In vivo Sister chromatid 
exchange 
Mouse bone marrow cells, alveolar 
macrophages, and regenerating liver cells 
 IP injection 0, 200 mg/kg Negative (Cheng & Kligerman, 1984) 1. 
Limited quality since only two 
animals were used and only 20 
metaphases were analysed for each 
cell type from each animal. Only one 
dose tested. 
In vivo Sex- linked 
recessive lethal test 
D. melanogaster Oral 0, 100, 500, 1000 
µg/ml 
Negative (Sernau, 1989) 1. 
Acceptable quality. GLP study 
generally in accordance with OECD 
477 (1984). 
(3-Methylphenol [04.026]) In vivo Sister chromatid 
exchange 
Mouse bone marrow cells, alveolar 
macrophages, and regenerating liver cells 
IP injection 0, 200 mg/kg Negative (Cheng & Kligerman, 1984) 1. 
Limited quality since only three 
animals were used and only 20 
metaphases were analysed for each 
cell type from each animal. Only one 
dose tested. 
In vivo Chromosome 
aberration assay 
Mouse bone marrow Oral (gavage) 0, 96, 320, 960 
mg/kg 
Negative (Ivett et al., 1989) 1. 
GLP study in accordance with OECD 
guideline 475 (1984).  
However, the validity of the result 
cannot be evaluated as all pages with 
results in table format are lacking. 
(4-Methylphenol [04.028]) In vivo Sister chromatid 
exchange 
Mouse bone marrow cells, alveolar 
macrophages, and regenerating liver cells 
IP injection 0, 75 mg/kg Negative (Cheng & Kligerman, 1984) 1. 
Limited quality since only three 
animals were used and only 20 
metaphases were analysed for each 
cell type from each animal. Only one 
dose tested. 
(Carvacrol [04.031]) 
 
In vivo Spot test D. melanogaster BINSC; Oregon-R  1.40 ppm;  
0.35 ppm 
Negative (Kono et al., 1995) 1. 
Validity cannot be evaluated. 
Publication is in Japanese with a 
short summary in English. Results 
reported only for two doses in table 
format. Not clear if control groups 
were treated concomitantly. 
4-Methoxyphenol [04.077] In vivo Chromosome 
aberration assay 
Rat Oral (gavage) 0, 100, 333, 1000 
mg/kg bw 
Negative (Esber, 1986) The study design was in accordance 
with OECD guideline 475 (1984). 
The study was incompletely reported, 
however, the study report contained 
sufficient  details to conclude that the 
outcome of the study is negative. 
1)  Summarised by JECFA, 55th meeting (JECFA, 2001b). 
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 ABBREVIATIONS 
ADI  Acceptable Daily Intake 
BW  Body weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CLr  Renal Clearance 
CLt  Total Clearance 
CoE  Council of Europe 
DMP  Dimethylphenol 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GI   Gastro intestinal 
GLP  Good Laboratory Practice 
GSH  Glutathione 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50%; Median lethal dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate, reduced form 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
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OECD  Organisation for Economic Co-operation and Development 
QM  Quinone methide 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
Vd   Volume of distribution  
WHO  World Health Organisation 
 
